Advanced search
Publication Cover
International Reviews of Immunology Volume 40, 2021 - Issue 1-2: Biology of Coronavirus Disease
Submit an article Journal homepage
2,436
Views
15
CrossRef citations to date
0
Altmetric
Review

Emerging Human Coronavirus Infections (SARS, MERS, and COVID-19): Where They Are Leading Us

Vijay Kumara Children’s Health Queensland Clinical Unit, School of Clinical Medicine, Faculty of Medicine, Mater Research, University of Queensland, Brisbane, Queensland, Australia;b School of Biomedical Sciences, Faculty of Medicine, University of Queensland, Brisbane, Queensland, AustraliaCorrespondence[email protected]
Pages 5-53 | Received 13 Jun 2020, Accepted 19 Jul 2020, Published online: 03 Aug 2020

References

  • Monto AS. Medical reviews. Coronaviruses. Yale J Biol Med. 1974;47(4):234–251.
  • Tyrrell DA, Bynoe ML. Cultivation of viruses from a high proportion of patients with colds. Lancet. 1966;1(7428):76–77. doi:10.1016/S0140-6736(66)92364-6.
  • Hamre D, Procknow JJ. A new virus isolated from the human respiratory tract. Proc Soc Exp Biol Med. 1966;121(1):190–193. doi:10.3181/00379727-121-30734.
  • McIntosh K, Dees JH, Becker WB, et al. Recovery in tracheal organ cultures of novel viruses from patients with respiratory disease. Proc Natl Acad Sci USA. 1967;57(4):933–940. doi:10.1073/pnas.57.4.933.
  • Almeida JD, Tyrrell DA. The morphology of three previously uncharacterized human respiratory viruses that grow in organ culture. J Gen Virol. 1967;1(2):175–178. doi:10.1099/0022-1317-1-2-175.
  • Tyrrell DA, Bynoe ML, Hoorn B. Cultivation of “difficult” viruses from patients with common colds. Br Med J. 1968;1(5592):606–610. doi:10.1136/bmj.1.5592.606.
  • Ksiazek TG, Erdman D, Goldsmith CS, et al. A novel coronavirus associated with severe acute respiratory syndrome. N Engl J Med. 2003;348(20):1953–1966. doi:10.1056/NEJMoa030781.
  • van der Hoek L, Pyrc K, Jebbink MF, et al. Identification of a new human coronavirus. Nat Med. 2004;10(4):368–373. doi:10.1038/nm1024.
  • Zaki AM, van Boheemen S, Bestebroer TM, et al. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N Engl J Med. 2012;367(19):1814–1820. doi:10.1056/NEJMoa1211721.
  • de Groot RJ, Baker SC, Baric RS, et al. Middle East respiratory syndrome coronavirus (MERS-CoV): announcement of the Coronavirus Study Group. J Virol. 2013;87(14):7790–7792. doi:10.1128/JVI.01244-13.
  • Wu F, Zhao S, Yu B, et al. A new coronavirus associated with human respiratory disease in China. Nature. 2020;579(7798):265–269. doi:10.1038/s41586-020-2008-3.
  • Gorbalenya AE, Baker SC, Baric RS, et al. The species severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. Nat Microbiol. 2020;5:536–544.
  • Hu D, Zhu C, Ai L, et al. Genomic characterization and infectivity of a novel SARS-like coronavirus in Chinese bats. Emerg Microbes Infect. 2018;7(1):154. doi:10.1038/s41426-018-0155-5.
  • Lu R, Zhao X, Li J, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020;395(10224):565–574. doi:10.1016/S0140-6736(20)30251-8.
  • de Vries AAF, Horzinek MC, Rottier PJM, et al. The genome organization of the nidovirales: similarities and differences between arteri-, toro-, and coronaviruses. Semin Virol. 1997;8(1):33–47. doi:10.1006/smvy.1997.0104.
  • Yang D, Leibowitz JL. The structure and functions of coronavirus genomic 3' and 5' ends. Virus Res. 2015;206:120–133. doi:10.1016/j.virusres.2015.02.025.
  • Drexler JF, Corman VM, Drosten C. Ecology, evolution and classification of bat coronaviruses in the aftermath of SARS. Antiviral Res. 2014;101:45–56. doi:10.1016/j.antiviral.2013.10.013.
  • Corman VM, Ithete NL, Richards LR, et al. Rooting the phylogenetic tree of middle East respiratory syndrome coronavirus by characterization of a conspecific virus from an African bat. J Virol. 2014;88(19):11297–11303. doi:10.1128/JVI.01498-14.
  • Wang Q, Qi J, Yuan Y, et al. Bat origins of MERS-CoV supported by bat coronavirus HKU4 usage of human receptor CD26. Cell Host Microbe. 2014;16(3):328–337. doi:10.1016/j.chom.2014.08.009.
  • Su S, Wong G, Shi W, et al. Epidemiology, genetic recombination, and pathogenesis of coronaviruses. Trends Microbiol. 2016;24(6):490–502. doi:10.1016/j.tim.2016.03.003.
  • Tu C, Crameri G, Kong X, et al. Antibodies to SARS coronavirus in civets. Emerging Infect Dis. 2004;10(12):2244–2248. doi:10.3201/eid1012.040520.
  • Xu R-H, He J-F, Evans MR, et al. Epidemiologic clues to SARS origin in China. Emerg Infect Dis. 2004;10(6):1030–1037. doi:10.3201/eid1006.030852.
  • Kan B, Wang M, Jing H, et al. Molecular evolution analysis and geographic investigation of severe acute respiratory syndrome coronavirus-like virus in palm civets at an animal market and on farms. J Virol. 2005;79(18):11892–11900. doi:10.1128/JVI.79.18.11892-11900.2005.
  • Wang M, Yan M, Xu H, et al. SARS-CoV infection in a restaurant from palm civet. Emerging Infect Dis. 2005;11(12):1860–1865. doi:10.3201/eid1112.041293.
  • Xu H, Wang M, Zhang Z, et al. An epidemiologic investigation on infection with severe acute respiratory syndrome coronavirus in wild animals traders in Guangzhou. Zhonghua yu fang yi xue za zhi [Chinese Journal of Preventive Medicine]. 2004;38:81–83.
  • Shi Z, Hu Z. A review of studies on animal reservoirs of the SARS coronavirus. Virus Res. 2008;133(1):74–87. doi:10.1016/j.virusres.2007.03.012.
  • Allocati N, Petrucci AG, Di Giovanni P, et al. Bat-man disease transmission: zoonotic pathogens from wildlife reservoirs to human populations. Cell Death Discov. 2016;2:16048. doi:10.1038/cddiscovery.2016.48.
  • Calisher CH, Childs JE, Field HE, et al. Bats: important reservoir hosts of emerging viruses. Clin Microbiol Rev. 2006;19(3):531–545. doi:10.1128/CMR.00017-06.
  • Wang L-F, Shi Z, Zhang S, et al. Review of bats and SARS. Emerging Infect Dis. 2006;12(12):1834–1840. doi:10.3201/eid1212.060401.
  • Wang LF, Eaton BT. Bats, civets and the emergence of SARS. Curr Top Microbiol Immunol. 2007;315:325–344. doi:10.1007/978-3-540-70962-6_13.
  • Lau SKP, Woo PCY, Li KSM, et al. Severe acute respiratory syndrome coronavirus-like virus in Chinese horseshoe bats. Proc Natl Acad Sci USA. 2005;102(39):14040–14045. doi:10.1073/pnas.0506735102.
  • Ren W, Qu X, Li W, et al. Difference in receptor usage between severe acute respiratory syndrome (SARS) coronavirus and SARS-like coronavirus of bat origin. J Virol. 2008;82(4):1899–1907. doi:10.1128/JVI.01085-07.
  • Hon C-C, Lam T-Y, Shi Z-L, et al. Evidence of the recombinant origin of a bat severe acute respiratory syndrome (SARS)-like coronavirus and its implications on the direct ancestor of SARS coronavirus. J Virol. 2008;82(4):1819–1826. doi:10.1128/JVI.01926-07.
  • Ge X-Y, Li J-L, Yang X-L, et al. Isolation and characterization of a bat SARS-like coronavirus that uses the ACE2 receptor. Nature. 2013;503(7477):535–538. doi:10.1038/nature12711.
  • Yang X-L, Hu B, Wang B, et al. Isolation and characterization of a novel bat coronavirus closely related to the direct progenitor of severe acute respiratory syndrome coronavirus. J Virol. 2015;90(6):3253–3256. doi:10.1128/JVI.02582-15.
  • Hu B, Zeng LP, Yang XL, et al. Discovery of a rich gene pool of bat SARS-related coronaviruses provides new insights into the origin of SARS coronavirus. PLoS Pathog. 2017;13(11):e1006698. doi:10.1371/journal.ppat.1006698.
  • Hu B, Ge X, Wang LF, et al. Bat origin of human coronaviruses. Virol J. 2015;12:221doi:10.1186/s12985-015-0422-1.
  • Chowell G, Abdirizak F, Lee S, et al. Transmission characteristics of MERS and SARS in the healthcare setting: a comparative study. BMC Med. 2015;13(1):210. doi:10.1186/s12916-015-0450-0.
  • Hunter JC, Nguyen D, Aden B, et al. Transmission of Middle East respiratory syndrome coronavirus infections in healthcare settings, Abu Dhabi. Emerging Infect Dis. 2016;22(4):647–656. doi:10.3201/eid2204.151615.
  • de Wit E, van Doremalen N, Falzarano D, et al. SARS and MERS: recent insights into emerging coronaviruses. Nat Rev Microbiol. 2016;14(8):523–534. doi:10.1038/nrmicro.2016.81.
  • Zhou P, Yang XL, Wang XG, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;579(7798):270–273. doi:10.1038/s41586-020-2012-7.
  • Yuen K-S, Ye Z-W, Fung S-Y, et al. SARS-CoV-2 and COVID-19: The most important research questions. Cell Biosci. 2020;10:40–40. doi:10.1186/s13578-020-00404-4.
  • Shang J, Ye G, Shi K, et al. Structural basis of receptor recognition by SARS-CoV-2. Nature. 2020;581(7807):221–224. doi:10.1038/s41586-020-2179-y.
  • Lam TT-Y, Shum MH-H, Zhu H-C, et al. Identifying SARS-CoV-2 related coronaviruses in Malayan pangolins. Nature. 2020;583(7815):282–285.
  • Ji W, Wang W, Zhao X, et al. Cross-species transmission of the newly identified coronavirus 2019-nCoV. J Med Virol. 2020;92(4):433–440. doi:10.1002/jmv.25682.
  • Zhang T, Wu Q, Zhang Z. Probable Pangolin origin of SARS-CoV-2 associated with the COVID-19 outbreak. Curr Biol. 2020;30(7):1346–1351.e2.
  • Coutard B, Valle C, de Lamballerie X, et al. The spike glycoprotein of the new coronavirus 2019-nCoV contains a furin-like cleavage site absent in CoV of the same clade. Antiviral Res. 2020;176:104742. doi:10.1016/j.antiviral.2020.104742.
  • Li X, Zai J, Zhao Q, et al. Evolutionary history, potential intermediate animal host, and cross-species analyses of SARS-CoV-2. J Med Virol. 2020;92(6):602–611. doi:10.1002/jmv.25731.
  • Stadler K, Masignani V, Eickmann M, et al. SARS-beginning to understand a new virus. Nat Rev Microbiol. 2003;1(3):209–218. doi:10.1038/nrmicro775.
  • Weiss SR, Leibowitz JL. 2008. Pathogenesis of murine coronavirus infection. In: Perlman S, Snijder E, eds. Nidoviruses. Washington, DC: American Society of Microbiology, ASM Press. p. 259–278.
  • Bender SJ, Weiss SR. Pathogenesis of murine coronavirus in the central nervous system. J Neuroimmune Pharmacol. 2010;5(3):336–354. doi:10.1007/s11481-010-9202-2.
  • Zhao L, Jha BK, Wu A, et al. Antagonism of the interferon-induced OAS-RNase L pathway by murine coronavirus ns2 protein is required for virus replication and liver pathology. Cell Host Microbe. 2012;11(6):607–616. doi:10.1016/j.chom.2012.04.011.
  • Dong B, Silverman RH. 2-5A-dependent RNase molecules dimerize during activation by 2-5A. J Biol Chem. 1995;270(8):4133–4137. doi:10.1074/jbc.270.8.4133.
  • Sadler AJ, Williams BR. Interferon-inducible antiviral effectors. Nat Rev Immunol. 2008;8(7):559–568. doi:10.1038/nri2314.
  • Kubota K, Nakahara K, Ohtsuka T, et al. Identification of 2'-phosphodiesterase, which plays a role in the 2-5A system regulated by interferon. J Biol Chem. 2004;279(36):37832–37841. doi:10.1074/jbc.M400089200.
  • Isaacs D, Flowers D, Clarke J, et al. Epidemiology of coronavirus respiratory infections. Arch Dis Child. 1983;58(7):500–503. doi:10.1136/adc.58.7.500.
  • Tortorici MA, Veesler D. Structural insights into coronavirus entry. Adv Virus Res. 2019;105:93–116. doi:10.1016/bs.aivir.2019.08.002.
  • Gu J, Korteweg C. Pathology and pathogenesis of severe acute respiratory syndrome. Am J Pathol. 2007;170(4):1136–1147. doi:10.2353/ajpath.2007.061088.
  • Nie Q-H, Luo X-D, Zhang J-Z, et al. Current status of severe acute respiratory syndrome in China. World J Gastroenterol. 2003;9(8):1635–1645. doi:10.3748/wjg.v9.i8.1635.
  • Severe acute respiratory syndrome (SARS): status of the outbreak and lessons for the immediate future. World Health Organization Communicable Disease Surveillance and Response; 2003p. 1–13.
  • Reilley B, Van Herp M, Sermand D, et al. SARS and Carlo Urbani. N Engl J Med. 2003;348(20):1951–1952. doi:10.1056/NEJMp030080.
  • Srikantiah P, Charles MD, Reagan S, et al. SARS clinical features, United States, 2003. Emerging Infect Dis. 2005;11(1):135–138. doi:10.3201/eid1101.040585.
  • Booth CM, Matukas LM, Tomlinson GA, et al. Clinical features and short-term outcomes of 144 patients with SARS in the greater Toronto area. JAMA. 2003;289(21):2801–2809. doi:10.1001/jama.289.21.JOC30885.
  • Choi KW, Chau TN, Tsang O, et al. Outcomes and prognostic factors in 267 patients with severe acute respiratory syndrome in Hong Kong. Ann Intern Med. 2003;139(9):715–723. doi:10.7326/0003-4819-139-9-200311040-00005.
  • Leung CW, Chiu WK. Clinical picture, diagnosis, treatment and outcome of severe acute respiratory syndrome (SARS) in children. Paediatr Respir Rev. 2004;5(4):275–288. doi:10.1016/j.prrv.2004.07.010.
  • Leung CW, Kwan YW, Ko PW, et al. Severe acute respiratory syndrome among children. Pediatrics. 2004;113(6):e535-43–e543. doi:10.1542/peds.113.6.e535.
  • Stockman LJ, Massoudi MS, Helfand R, et al. Severe acute respiratory syndrome in children. Pediatr Infect Dis J. 2007;26(1):68–74. doi:10.1097/01.inf.0000247136.28950.41.
  • Li AM, Ng PC. Severe acute respiratory syndrome (SARS) in neonates and children. Arch Dis Child Fetal Neonatal Ed. 2005;90(6):F461–5. doi:10.1136/adc.2005.075309.
  • Wong SF, Chow KM, Leung TN, et al. Pregnancy and perinatal outcomes of women with severe acute respiratory syndrome. Am J Obstet Gynecol. 2004;191(1):292–297. doi:10.1016/j.ajog.2003.11.019.
  • Yudin MH, Steele DM, Sgro MD, et al. Severe acute respiratory syndrome in pregnancy. Obstet Gynecol. 2005;105(1):124–127. doi:10.1097/01.AOG.0000151598.49129.de.
  • Shek CC, Ng PC, Fung GP, et al. Infants born to mothers with severe acute respiratory syndrome. Pediatrics. 2003;112(4):e254. doi:10.1542/peds.112.4.e254.
  • Ksiezakowska K, Laszczyk M, Wilczyński J, et al. SARS-CoV infection and pregnancy. Ginekol Pol. 2008;79(1):47–50.
  • Ng WF, Wong SF, Lam A, et al. The placentas of patients with severe acute respiratory syndrome: a pathophysiological evaluation. Pathology. 2006;38(3):210–218. doi:10.1080/00313020600696280.
  • Chen W, Yan M, Yang L, et al. SARS-associated coronavirus transmitted from human to pig. Emerging Infect Dis. 2005;11(3):446–448. doi:10.3201/eid1103.040824.
  • Daszak P, Lipkin WI. The search for meaning in virus discovery. Curr Opin Virol. 2011;1(6):620–623. doi:10.1016/j.coviro.2011.10.010.
  • Zhong NS, Zheng BJ, Li YM, et al. Epidemiology and cause of severe acute respiratory syndrome (SARS) in Guangdong, People's Republic of China, in February, 2003. Lancet. 2003;362(9393):1353–1358. doi:10.1016/S0140-6736(03)14630-2.
  • Zumla A, Hui DS, Perlman S. Middle East respiratory syndrome. Lancet. 2015;386(9997):995–1007. doi:10.1016/S0140-6736(15)60454-8.
  • Mackay IM, Arden KE. Middle East respiratory syndrome: an emerging coronavirus infection tracked by the crowd. Virus Res. 2015;202:60–88. doi:10.1016/j.virusres.2015.01.021.
  • Bermingham A, Chand MA, Brown CS, et al. Severe respiratory illness caused by a novel coronavirus, in a patient transferred to the United Kingdom from the Middle East, September 2012. Euro Surveill. 2012;17:20290.
  • News DO. 2020. Middle East respiratory syndrome coronavirus (MERS-CoV) – The Kingdom of Saudi Arabia.
  • WHO. 2019. Middle East respiratory syndrome coronavirus (MERS-CoV).
  • Reusken CBEM, Haagmans BL, Müller MA, et al. Middle East respiratory syndrome coronavirus neutralising serum antibodies in dromedary camels: a comparative serological study. Lancet Infect Dis. 2013;13(10):859–866. doi:10.1016/S1473-3099(13)70164-6.
  • Haagmans BL, Al Dhahiry SHS, Reusken CBEM, et al. Middle East respiratory syndrome coronavirus in dromedary camels: an outbreak investigation. Lancet Infect Dis. 2014;14(2):140–145. doi:10.1016/S1473-3099(13)70690-X.
  • Coleman CM, Frieman MB. Coronaviruses: important emerging human pathogens. J Virol. 2014;88(10):5209–5212. doi:10.1128/JVI.03488-13.
  • Hui DS, Memish ZA, Zumla A. Severe acute respiratory syndrome vs. the Middle East respiratory syndrome. Curr Opin Pulm Med. 2014;20(3):233–241. doi:10.1097/MCP.0000000000000046.
  • Who Mers-Cov Research Group. State of knowledge and data gaps of Middle East respiratory syndrome coronavirus (MERS-CoV) in humans. PLoS Curr. 2013;5.
  • Tsiodras S, Baka A, Mentis A, et al. A case of imported Middle East Respiratory Syndrome coronavirus infection and public health response, Greece, April 2014. Euro Surveill. 2014;19:20782.
  • Alsaad KO, Hajeer AH, Al Balwi M, et al. Histopathology of Middle East respiratory syndrome coronovirus (MERS-CoV) infection - clinicopathological and ultrastructural study. Histopathology. 2018;72(3):516–524. doi:10.1111/his.13379.
  • Kulcsar KA, Coleman CM, Beck SE, et al. Comorbid diabetes results in immune dysregulation and enhanced disease severity following MERS-CoV infection. JCI Insight. 2019;4:20. doi:10.1172/jci.insight.131774.
  • Meyerholz DK, Lambertz AM, McCray PB Jr. Dipeptidyl peptidase 4 distribution in the human respiratory tract: implications for the Middle East respiratory syndrome. Am J Pathol. 2016;186(1):78–86. doi:10.1016/j.ajpath.2015.09.014.
  • Seys LJM, Widagdo W, Verhamme FM, et al. DPP4, the Middle East respiratory syndrome coronavirus receptor, is upregulated in lungs of smokers and chronic obstructive pulmonary disease patients. Clin Infect Dis. 2018;66(1):45–53. doi:10.1093/cid/cix741.
  • Memish ZA, Al-Tawfiq JA, Assiri A, et al. Middle East respiratory syndrome coronavirus disease in children. Pediatr Infect Dis J. 2014;33(9):904–906. doi:10.1097/INF.0000000000000325.
  • Alfaraj SH, Al-Tawfiq JA, Altuwaijri TA, et al. Middle East respiratory syndrome coronavirus in pediatrics: a report of seven cases from Saudi Arabia. Front Med. 2019;13(1):126–130. doi:10.1007/s11684-017-0603-y.
  • Centre for Health Protection of the Hong Kong Special Administrative Region Government. CHP closely monitors cluster of pneumonia cases on Mainland. 2019.
  • Chan JF-W, Yuan S, Kok K-H, et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet. 2020;395(10223):514–523. doi:10.1016/S0140-6736(20)30154-9.
  • Kong W-H, Li Y, Peng M-W, et al. SARS-CoV-2 detection in patients with influenza-like illness. Nat Microbiol. 2020;5(5):675–678. ) doi:10.1038/s41564-020-0713-1.
  • Mao L, Jin H, Wang M, et al. Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China. JAMA Neurol. 2020;77(6):683–690. doi:10.1001/jamaneurol.2020.1127.
  • Giacomelli A, Pezzati L, Conti F, et al. Self-reported olfactory and taste disorders in SARS-CoV-2 patients: a cross-sectional study. Clin Infect Dis. 2020;ciaa330. doi:10.1093/cid/ciaa330.
  • Whitcroft KL, Hummel T. Olfactory dysfunction in COVID-19: diagnosis and management. JAMA. 2020;323(24):2512–2514. doi:10.1001/jama.2020.8391.
  • Costa K, Carnaúba ATL, Rocha KW, et al. Olfactory and taste disorders in COVID-19: a systematic review. Braz J Otorhinolaryngol. 2020.
  • Guan W-j, Ni Z-y, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. N Eng J Med. 2020.
  • Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497–506. doi:10.1016/S0140-6736(20)30183-5.
  • Chang D, Lin M, Wei L, et al. Epidemiologic and clinical characteristics of novel coronavirus infections involving 13 patients outside Wuhan, China. JAMA. 2020;323(11):1092–1093. doi:10.1001/jama.2020.1623.
  • Xu P, Zhou Q, Xu J. Mechanism of thrombocytopenia in COVID-19 patients. Ann Hematol. 2020;99(6):1205–1208. doi:10.1007/s00277-020-04019-0.
  • Gu J, Han B, Wang J. COVID-19: gastrointestinal manifestations and potential fecal–oral transmission. Gastroenterology. 2020;158(6):1518–1519. doi:10.1053/j.gastro.2020.02.054.
  • Lamers MM, Beumer J, van der Vaart J, et al. SARS-CoV-2 productively infects human gut enterocytes. Science. 2020;369(6499):50–54. doi:10.1126/science.abc1669.
  • Fan C, Li K, Ding Y, et al. ACE2 expression in kidney and testis may cause kidney and testis damage after 2019-nCoV infection. medRxiv.2020.02.12.20022418.
  • Rabb H. Kidney diseases in the time of COVID-19: major challenges to patient care. J Clin Invest. 2020;130(6):2749–2751. doi:10.1172/JCI138871.
  • Zhang JW, Wang Y, Lu R, et al. 2020. Bioinformatic analysis reveals that the reproductive system is potentially at risk from SARS-CoV-2. Preprints.
  • Vaz-Silva J, Carneiro MM, Ferreira MC, et al. The vasoactive peptide angiotensin-(1-7), its receptor Mas and the angiotensin-converting enzyme type 2 are expressed in the human endometrium. Reprod Sci. 2009;16(3):247–256. doi:10.1177/1933719108327593.
  • Reis FM, Bouissou DR, Pereira VM, et al. Angiotensin-(1-7), its receptor Mas, and the angiotensin-converting enzyme type 2 are expressed in the human ovary. Fertil Steril. 2011;95(1):176–181. doi:10.1016/j.fertnstert.2010.06.060.
  • Sun J, Zhu A, Li H, et al. Isolation of infectious SARS-CoV-2 from urine of a COVID-19 patient. Emerg Microbes Infect. 2020;9(1):991–993. doi:10.1080/22221751.2020.1760144.
  • Nomoto H, Ishikane M, Katagiri D, et al. Cautious handling of urine from moderate to severe COVID-19 patients. Am J Infect Control. 2020.
  • Randazzo W, Truchado P, Cuevas-Ferrando E, et al. SARS-CoV-2 RNA in wastewater anticipated COVID-19 occurrence in a low prevalence area. Water Res. 2020;181:115942. doi:10.1016/j.watres.2020.115942.
  • Pan F, Xiao X, Guo J, et al. No evidence of severe acute respiratory syndrome-coronavirus 2 in semen of males recovering from coronavirus disease 2019. Fertil Steril. 2020;113(6):1135–1139. doi:10.1016/j.fertnstert.2020.04.024.
  • Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395(10223):507–513. doi:10.1016/S0140-6736(20)30211-7.
  • Scully EP, Haverfield J, Ursin RL, et al. Considering how biological sex impacts immune responses and COVID-19 outcomes. Nat Rev Immunol. 2020;20(7):442–447. doi:10.1038/s41577-020-0348-8.
  • Jin J-M, Bai P, He W, et al. Gender differences in patients with COVID-19: focus on severity and mortality. Front Public Health. 2020;8:152–152. doi:10.3389/fpubh.2020.00152.
  • Peckham H, de Gruijter, NM, Charles R, et al. Sex-bias in COVID-19: a meta-analysis and review of sex differences in disease and immunity. Lancet Infect Dis. 2020.
  • Chen H, Guo J, Wang C, et al. Clinical characteristics and intrauterine vertical transmission potential of COVID-19 infection in nine pregnant women: a retrospective review of medical records. Lancet. 2020;395(10226):809–815. doi:10.1016/S0140-6736(20)30360-3.
  • Liu Y, Chen H, Tang K, et al. Clinical manifestations and outcome of SARS-CoV-2 infection during pregnancy. J Infect. 2020. doi:10.1016/j.jinf.2020.02.028.
  • Zhu H, Wang L, Fang C, et al. Clinical analysis of 10 neonates born to mothers with 2019-nCoV pneumonia. Transl Pediatr. 2020;9(1):51–60. doi:10.21037/tp.2020.02.06.
  • Hosier H, Farhadian SF, Morotti RA, et al. SARS-CoV-2 infection of the placenta. J Clin Invest. 2020;
  • Di Mascio D, Khalil A, Saccone G, et al. Outcome of Coronavirus spectrum infections (SARS, MERS, COVID 1 -19) during pregnancy: a systematic review and meta-analysis. Am J Obstet Gynecol MFM. 2020;2(2):100107. doi:10.1016/j.ajogmf.2020.100107.
  • Juan J, Gil MM, Rong Z, et al. Effects of coronavirus disease 2019 (COVID-19) on maternal, perinatal and neonatal outcomes: a systematic review. Ultrasound Obstet Gynecol. 2020;56(1):15–27. ) doi:10.1002/uog.22088.
  • Price-Haywood EG, Burton J, Fort D, et al. Hospitalization and mortality among Black patients and White patients with Covid-19. N Engl J Med. 2020;382(26):2534–2543. doi:10.1056/NEJMsa2011686.
  • African-American Population is More Vulnerable to Sars-CoV2 Infection and IFN-Beta Supplement Can Be an Effective Treatment. SSRN. 2020:1–13.
  • Ellinghaus D, Degenhardt F, Bujanda L, et al. Genomewide Association Study of Severe Covid-19 with respiratory failure. N Engl J Med. 2020;
  • Kroczek R, Henn V. The role of XCR1 and its lligand XCL1 in antigen cross-presentation by murine and human dendritic cells. Front Immunol. 2012;3:14. doi:10.3389/fimmu.2012.00014.
  • Chen T, Wu D, Chen H, et al. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. BMJ. 2020;368:m1091.
  • Ji H-L, Zhao R, Matalon S, Matthay MA. Elevated plasmin(ogen) as a common risk factor for COVID-19 susceptibility. Physiol Rev. 2020;100(3):1065–1075. doi:10.1152/physrev.00013.2020.
  • Klok FA, Kruip M, van der Meer NJM, et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res. 2020;191:145–147. doi:10.1016/j.thromres.2020.04.013.
  • Middeldorp S, Coppens M, van Haaps TF, et al. Incidence of venous thromboembolism in hospitalized patients with COVID‐19. J Thromb Haemost. 2020.
  • Lodigiani C, Iapichino G, Carenzo L, et al. Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital in Milan, Italy. Thromb Res. 2020;191:9–14. doi:10.1016/j.thromres.2020.04.024.
  • Martinelli I, Ferrazzi E, Ciavarella A, et al. Pulmonary embolism in a young pregnant woman with COVID-19. Thromb Res. 2020;191:36–37. doi:10.1016/j.thromres.2020.04.022.
  • van Nieuwkoop C. COVID-19 associated pulmonary thrombosis. Thromb Res. 2020;191:151–151. doi:10.1016/j.thromres.2020.04.042.
  • Price LC, McCabe C, Garfield B, et al. Thrombosis and COVID-19 pneumonia: the clot thickens! Eur Resp J. 2020;2001608.
  • Rapkiewicz AV, Mai X, Carsons SE, et al. Megakaryocytes and platelet-fibrin thrombi characterize multi-organ thrombosis at autopsy in COVID-19: a case series. EClinicalMedicine.
  • Connors JM, Levy JH. COVID-19 and its implications for thrombosis and anticoagulation. Blood. 2020;135(23):2033–2040. doi:10.1182/blood.2020006000.
  • Kalinskaya A, Dukhin O, Molodtsov I, et al. Dynamics of coagulopathy in patients with different COVID-19 severity. medRxiv. 2020.
  • Kelvin AA, Halperin S. COVID-19 in children: the link in the transmission chain. Lancet Infect Dis. 2020;20(6):633–634. doi:10.1016/S1473-3099(20)30236-X.
  • Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. JAMA. 2020;323(13):1239. doi:10.1001/jama.2020.2648.
  • Qiu H, Wu J, Hong L, et al. Clinical and epidemiological features of 36 children with coronavirus disease 2019 (COVID-19) in Zhejiang, China: an observational cohort study. Lancet Infect Dis. 2020;20(6):689–696. doi:10.1016/S1473-3099(20)30198-5.
  • Wang L, Shi Y, Xiao T, et al. Chinese expert consensus on the perinatal and neonatal management for the prevention and control of the 2019 novel coronavirus infection (First edition). Ann Transl Med. 2020;8(3):47. doi:10.21037/atm.2020.02.20.
  • Heaney LG, Stevenson EC, Turner G, et al. Investigating paediatric airways by non-bronchoscopic lavage: normal cellular data. Clin Exp Allergy. 1996;26(7):799–806. doi:10.1111/j.1365-2222.1996.tb00611.x.
  • Midulla F, Villani A, Merolla R, et al. Bronchoalveolar lavage studies in children without parenchymal lung disease: cellular constituents and protein levels. Pediatr Pulmonol. 1995;20(2):112–118. doi:10.1002/ppul.1950200211.
  • Ratjen F, Bredendiek M, Brendel M, et al. Differential cytology of bronchoalveolar lavage fluid in normal children. Eur Respir J. 1994;7(10):1865–1870. doi:10.1183/09031936.94.07101865.
  • Gidaris D, Kanakoudi-Tsakalidou F, Papakosta D, et al. Bronchoalveolar lavage in children with inflammatory and non inflammatory lung disease. Hippokratia. 2010;14(2):109–114.
  • Grigg J, Riedler J, Robertson CF, et al. Alveolar macrophage immaturity in infants and young children. Eur Respir J. 1999;14(5):1198–1205. doi:10.1183/09031936.99.14511989.
  • Schouten LR, van Kaam AH, Kohse F, et al. Age-dependent differences in pulmonary host responses in ARDS: a prospective observational cohort study. Ann Intens Care. 2019;9(1):55. doi:10.1186/s13613-019-0529-4.
  • Georgountzou A, Papadopoulos NG. Postnatal innate immune development: from birth to adulthood. Front Immunol. 2017;8:957–957. doi:10.3389/fimmu.2017.00957.
  • Starner TD, Agerberth B, Gudmundsson GH, et al. Expression and activity of beta-defensins and LL-37 in the developing human lung. J Immunol. 2005;174(3):1608–1615. doi:10.4049/jimmunol.174.3.1608.
  • Pandya VK, Tiwari RS. Nasal mucociliary clearance in health and disease. Indian J Otolaryngol Head Neck Surg. 2006;58(4):332–334. doi:10.1007/BF03049581.
  • Ardigo D, Valtuena S, Zavaroni I, et al. Pulmonary complications in diabetes mellitus: the role of glycemic control. Curr Drug Targets Inflamm Allergy. 2004;3(4):455–458. doi:10.2174/1568010042634488.
  • Ferlita S, Yegiazaryan A, Noori N, et al. Type 2 diabetes mellitus and altered immune system leading to susceptibility to pathogens, especially Mycobacterium tuberculosis. JCM. 2019;8(12):2219. doi:10.3390/jcm8122219.
  • Zhang C, Iftikhar H, Nair GB. Influence of diabetes mellitus-related immune dysfunction in hospitalized interstitial lung disease patients. Chest. 2018;154(4):403A. doi:10.1016/j.chest.2018.08.370.
  • O’Leary SM, Coleman MM, Chew WM, et al. Cigarette smoking impairs human pulmonary immunity to Mycobacterium tuberculosis. Am J Respir Crit Care Med. 2014;190(12):1430–1436. doi:10.1164/rccm.201407-1385OC.
  • Mancuso P. Obesity and lung inflammation. J Appl Physiol. 2010;108(3):722–728. doi:10.1152/japplphysiol.00781.2009.
  • Mafort TT, Rufino R, Costa CH, et al. Obesity: systemic and pulmonary complications, biochemical abnormalities, and impairment of lung function. Multidiscip Respir Med. 2016;11:28. doi:10.1186/s40248-016-0066-z.
  • Ogden CL, Carroll MD, Curtin LR, et al. Prevalence of overweight and obesity in the United States, 1999-2004. JAMA. 2006;295(13):1549–1555. doi:10.1001/jama.295.13.1549.
  • 2014. Current epidemiology of obesity in the United States. In Roundtable on Obesity Solutions Food and Nutrition Board Institute of Medicine. The Current State of Obesity Solutions in the United States: Workshop Summary. Washington, DC: National Academies Press.
  • Du P, Wang HJ, Zhang B, et al. Prevalence of abdominal obesity among Chinese adults in 2011. J Epidemiol. 2017;27(6):282–286. doi:10.1016/j.je.2017.03.001.
  • Liu X, Wu W, Mao Z, et al. Prevalence and influencing factors of overweight and obesity in a Chinese rural population: the Henan Rural Cohort Study. Sci Rep. 2018;8(1):13101–13101. doi:10.1038/s41598-018-31336-2.
  • Hu C, Jia W. Diabetes in China: epidemiology and genetic risk factors and their clinical utility in personalized medication. Diabetes. 2018;67(1):3–11. doi:10.2337/dbi17-0013.
  • Ma RCW. Epidemiology of diabetes and diabetic complications in China. Diabetologia. 2018;61(6):1249–1260. doi:10.1007/s00125-018-4557-7.
  • Lighter J, Phillips M, Hochman S, et al. Obesity in patients younger than 60 years is a risk factor for Covid-19 hospital admission. Clin Infect Dis. 2020; doi:10.1093/cid/ciaa415.
  • Cushman M. Epidemiology and risk factors for venous thrombosis. Semin Hematol. 2007;44(2):62–69. doi:10.1053/j.seminhematol.2007.02.004.
  • Guo T, Fan Y, Chen M, et al. Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19). JAMA Cardiol. 2020;5(7):811. doi:10.1001/jamacardio.2020.1017.
  • Welsh P, Preiss D, Hayward C, et al. Cardiac troponin T and troponin I in the general population. Circulation. 2019;139(24):2754–2764. doi:10.1161/CIRCULATIONAHA.118.038529.
  • Guo J, Huang Z, Lin L, Lv J. Coronavirus disease 2019 (COVID-19) and cardiovascular disease: a viewpoint on the potential influence of angiotensin-converting enzyme inhibitors/angiotensin receptor blockers on onset and severity of severe acute respiratory syndrome coronavirus 2 infection . J Am Heart Assoc. 2020;9(7):e016219. doi:10.1161/JAHA.120.016219.
  • Shi S, Qin M, Shen B, et al. Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan, China. JAMA Cardiol. 2020;5(7):802. doi:10.1001/jamacardio.2020.0950.
  • Der Sarkissian S, Grobe JL, Yuan L, et al. Cardiac overexpression of angiotensin converting enzyme 2 protects the heart from ischemia-induced pathophysiology. Hypertension. 2008;51(3):712–718. doi:10.1161/HYPERTENSIONAHA.107.100693.
  • Ferrario CM, Jessup J, Chappell MC, et al. Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2. Circulation. 2005;111(20):2605–2610. doi:10.1161/CIRCULATIONAHA.104.510461.
  • Ishiyama Y, Gallagher PE, Averill DB, et al. Upregulation of angiotensin-converting enzyme 2 after myocardial infarction by blockade of angiotensin II receptors. Hypertension. 2004;43(5):970–976. doi:10.1161/01.HYP.0000124667.34652.1a.
  • Kuba K, Imai Y, Rao S, et al. A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury. Nat Med. 2005;11(8):875–879. doi:10.1038/nm1267.
  • Alhazzani W, Møller MH, Arabi YM, et al. Surviving sepsis campaign: guidelines on the management of critically ill adults with coronavirus disease 2019 (COVID-19). Crit Care Med. 2020.
  • Alhazzani W, Møller MH, Arabi YM, et al. Surviving sepsis campaign: guidelines on the management of critically ill adults with Coronavirus Disease 2019 (COVID-19). Intens Care Med. 2020;46(5):854–887.
  • Masters PS. The molecular biology of coronaviruses. Adv Virus Res. 2006;66:193–292. doi:10.1016/S0065-3527(06)66005-3.
  • Grossoehme NE, Li L, Keane SC, et al. Coronavirus N protein N-terminal domain (NTD) specifically binds the transcriptional regulatory sequence (TRS) and melts TRS-cTRS RNA duplexes. J Mol Biol. 2009;394(3):544–557. doi:10.1016/j.jmb.2009.09.040.
  • Cong Y, Kriegenburg F, de Haan CAM, et al. Coronavirus nucleocapsid proteins assemble constitutively in high molecular oligomers. Sci Rep. 2017;7(1):5740. doi:10.1038/s41598-017-06062-w.
  • Hsin W-C, Chang C-H, Chang C-Y, et al. Nucleocapsid protein-dependent assembly of the RNA packaging signal of Middle East respiratory syndrome coronavirus. J Biomed Sci. 2018;25(1):47doi:10.1186/s12929-018-0449-x.
  • Millet JK, Whittaker GR. Host cell proteases: critical determinants of coronavirus tropism and pathogenesis. Virus Res. 2015;202:120–134. doi:10.1016/j.virusres.2014.11.021.
  • Walls AC, Park Y-J, Tortorici MA, et al. Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. Cell. 2020;181(2):281–292. doi:10.1016/j.cell.2020.02.058.
  • Wickramasinghe INA, van Beurden SJ, Weerts EAWS, et al. The avian coronavirus spike protein. Virus Res. 2014;194:37–48. doi:10.1016/j.virusres.2014.10.009.
  • Chen H, Wurm T, Britton P, et al. Interaction of the coronavirus nucleoprotein with nucleolar antigens and the host cell. J Virol. 2002;76(10):5233–5250. doi:10.1128/jvi.76.10.5233-5250.2002.
  • Fan H, Ooi A, Tan YW, et al. The nucleocapsid protein of coronavirus infectious bronchitis virus: crystal structure of its N-terminal domain and multimerization properties. Structure. 2005;13(12):1859–1868. doi:10.1016/j.str.2005.08.021.
  • Siu YL, Teoh KT, Lo J, et al. The M, E, and N structural proteins of the severe acute respiratory syndrome coronavirus are required for efficient assembly, trafficking, and release of virus-like particles. J Virol. 2008;82(22):11318–11330. doi:10.1128/JVI.01052-08.
  • Kirchdoerfer RN, Cottrell CA, Wang N, et al. Pre-fusion structure of a human coronavirus spike protein. Nature. 2016;531(7592):118–121. doi:10.1038/nature17200.
  • Song HC, Seo MY, Stadler K, et al. Synthesis and characterization of a native, oligomeric form of recombinant severe acute respiratory syndrome coronavirus spike glycoprotein. J Virol. 2004;78(19):10328–10335. doi:10.1128/JVI.78.19.10328-10335.2004.
  • Ho TY, Wu SL, Cheng SE, et al. Antigenicity and receptor-binding ability of recombinant SARS coronavirus spike protein. Biochem Biophys Res Commun. 2004;313(4):938–947. doi:10.1016/j.bbrc.2003.11.180.
  • Jia HP, Look DC, Shi L, et al. ACE2 receptor expression and severe acute respiratory syndrome coronavirus infection depend on differentiation of human airway epithelia. J Virol. 2005;79(23):14614–14621. doi:10.1128/JVI.79.23.14614-14621.2005.
  • Xu H, Zhong L, Deng J, et al. High expression of ACE2 receptor of 2019-nCoV on the epithelial cells of oral mucosa. Int J Oral Sci. 2020;12(1):8doi:10.1038/s41368-020-0074-x.
  • Zhang H, Kang Z, Gong H, et al. The digestive system is a potential route of 2019-nCov infection: a bioinformatics analysis based on single-cell transcriptomes. bioRxiv.2020.01.30.927806.
  • Chai X, Hu L, Zhang Y, et al. Specific ACE2 expression in cholangiocytes may cause liver damage after 2019-nCoV infection. 2020; bioRxiv.2020.02.03.931766.
  • Zou X, Chen K, Zou J, et al. Single-cell RNA-seq data analysis on the receptor ACE2 expression reveals the potential risk of different human organs vulnerable to 2019-nCoV infection. Front Med. 2020;14(2):185–192. doi:10.1007/s11684-020-0754-0.
  • Sungnak W, Huang N, Bécavin C, et al. SARS-CoV-2 entry factors are highly expressed in nasal epithelial cells together with innate immune genes. Nat Med. 2020;26(5):681–687.
  • Bosch BJ, van der Zee R, de Haan CA, et al. The coronavirus spike protein is a class I virus fusion protein: structural and functional characterization of the fusion core complex. J Virol. 2003;77(16):8801–8811. doi:10.1128/jvi.77.16.8801-8811.2003.
  • Li F. Structure, function, and evolution of coronavirus spike proteins. Annu Rev Virol. 2016;3(1):237–261. doi:10.1146/annurev-virology-110615-042301.
  • Wan Y, Shang J, Graham R, et al. Receptor recognition by the novel coronavirus from Wuhan: an analysis based on decade-long structural studies of SARS coronavirus. J Virol. 2020;94(7):e00127-20. doi:10.1128/JVI.00127-20.
  • Letko M, Marzi A, Munster V. Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses. Nat Microbiol. 2020;5(4):562–569. doi:10.1038/s41564-020-0688-y.
  • Schoeman D, Fielding BC. Coronavirus envelope protein: current knowledge. Virol J. 2019;16(1):69. doi:10.1186/s12985-019-1182-0.
  • Fehr AR, Perlman S. Coronaviruses: an overview of their replication and pathogenesis. Methods Mol Biol. 2015;1282:1–23. doi:10.1007/978-1-4939-2438-7_1.
  • Glowacka I, Bertram S, Müller MA, et al. Evidence that TMPRSS2 activates the severe acute respiratory syndrome coronavirus spike protein for membrane fusion and reduces viral control by the humoral immune response. J Virol. 2011;85(9):4122–4134. doi:10.1128/JVI.02232-10.
  • Chen L, Liu W, Zhang Q, et al. RNA based mNGS approach identifies a novel human coronavirus from two individual pneumonia cases in 2019 Wuhan outbreak. Emerg Microbes Infect. 2020;9(1):313–319. doi:10.1080/22221751.2020.1725399.
  • Sims AC, Baric RS, Yount B, et al. Severe acute respiratory syndrome coronavirus infection of human ciliated airway epithelia: role of ciliated cells in viral spread in the conducting airways of the lungs. J Virol. 2005;79(24):15511–15524. doi:10.1128/JVI.79.24.15511-15524.2005.
  • Li W, Moore MJ, Vasilieva N, et al. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature. 2003;426(6965):450–454. doi:10.1038/nature02145.
  • Turner AJ, Hiscox JA, Hooper NM. ACE2: from vasopeptidase to SARS virus receptor. Trends Pharmacol Sci. 2004;25(6):291–294. doi:10.1016/j.tips.2004.04.001.
  • Hou YJ, Okuda K, Edwards CE, et al. SARS-CoV-2 reverse genetics reveals a variable infection gradient in the respiratory tract. Cell. 2020;182(2):429–446.e14. doi:10.1016/j.cell.2020.05.042.
  • Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181(2):271–280. doi:10.1016/j.cell.2020.02.052.
  • Heurich A, Hofmann-Winkler H, Gierer S, et al. TMPRSS2 and ADAM17 cleave ACE2 differentially and only proteolysis by TMPRSS2 augments entry driven by the severe acute respiratory syndrome coronavirus spike protein. J Virol. 2014;88(2):1293–1307. doi:10.1128/JVI.02202-13.
  • Bosch BJ, Bartelink W, Rottier PJ. Cathepsin L functionally cleaves the severe acute respiratory syndrome coronavirus class I fusion protein upstream of rather than adjacent to the fusion peptide. J Virol. 2008;82(17):8887–8890. doi:10.1128/JVI.00415-08.
  • Simmons G, Gosalia DN, Rennekamp AJ, et al. Inhibitors of cathepsin L prevent severe acute respiratory syndrome coronavirus entry. Proc Natl Acad Sci USA. 2005;102(33):11876–11881. doi:10.1073/pnas.0505577102.
  • Ou X, Liu Y, Lei X, et al. Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV. Nat Commun. 2020;11(1):1620. doi:10.1038/s41467-020-15562-9.
  • Ferguson CJ, Lenk GM, Meisler MH. Defective autophagy in neurons and astrocytes from mice deficient in PI(3,5)P2. Hum Mol Genet. 2009;18(24):4868–4878. doi:10.1093/hmg/ddp460.
  • Rutherford AC, Traer C, Wassmer T, et al. The mammalian phosphatidylinositol 3-phosphate 5-kinase (PIKfyve) regulates endosome-to-TGN retrograde transport. J Cell Sci. 2006;119(Pt 19):3944–3957. doi:10.1242/jcs.03153.
  • de Lartigue J, Polson H, Feldman M, et al. PIKfyve regulation of endosome-linked pathways. Traffic. 2009;10(7):883–893. doi:10.1111/j.1600-0854.2009.00915.x.
  • Shisheva A. PIKfyve: Partners, significance, debates and paradoxes. Cell Biol Int. 2008;32(6):591–604. doi:10.1016/j.cellbi.2008.01.006.
  • Matsuyama S, Nao N, Shirato K, et al. Enhanced isolation of SARS-CoV-2 by TMPRSS2-expressing cells. Proc Natl Acad Sci USA. 2020;117(13):7001–7003. doi:10.1073/pnas.2002589117.
  • Shirato K, Kawase M, Matsuyama S. Middle East Respiratory syndrome coronavirus infection mediated by the transmembrane serine protease TMPRSS2. J Virol. 2013;87(23):12552–12561. doi:10.1128/JVI.01890-13.
  • Iwata-Yoshikawa N, Okamura T, Shimizu Y, et al. TMPRSS2 contributes to virus spread and immunopathology in the airways of murine models after coronavirus infection. J Virol. 2019;93(6) doi:10.1128/JVI.01815-18.
  • Braun E, Sauter D. Furin-mediated protein processing in infectious diseases and cancer. Clin Transl Immunol. 2019;8(8):e1073doi:10.1002/cti2.1073.
  • Uhlén M, Fagerberg L, Hallström BM, et al. Proteomics. Tissue-based map of the human proteome. Science. 2015;347(6220):1260419doi:10.1126/science.1260419.
  • Vähätupa M, Cordova ZM, Barker H, et al. Furin deficiency in myeloid cells leads to attenuated revascularization in a mouse-model of oxygen-induced retinopathy. Exp Eye Res. 2018;166:160–167. doi:10.1016/j.exer.2017.10.013.
  • Cordova ZM, Grönholm A, Kytölä V, et al. Myeloid cell expressed proprotein convertase FURIN attenuates inflammation. Oncotarget. 2016;7(34):54392–54404. doi:10.18632/oncotarget.11106.
  • Pesu M, Muul L, Kanno Y, et al. Proprotein convertase furin is preferentially expressed in T helper 1 cells and regulates interferon gamma. Blood. 2006;108(3):983–985. doi:10.1182/blood-2005-09-3824.
  • Blanchette F, Day R, Dong W, et al. TGFbeta1 regulates gene expression of its own converting enzyme furin. J Clin Invest. 1997;99(8):1974–1983. doi:10.1172/JCI119365.
  • Andersen KG, Rambaut A, Lipkin WI, et al. The proximal origin of SARS-CoV-2. Nat Med. 2020;26(4):450–452. doi:10.1038/s41591-020-0820-9.
  • Follis KE, York J, Nunberg JH. Furin cleavage of the SARS coronavirus spike glycoprotein enhances cell-cell fusion but does not affect virion entry. Virology. 2006;350(2):358–369. doi:10.1016/j.virol.2006.02.003.
  • Zhao X, Zheng S, Chen D, et al. LY6E restricts the entry of human coronaviruses, including the currently pandemic SARS-CoV-2. bioRxiv.2020.04.02.021469.
  • Lee PY, Wang J-X, Parisini E, et al. Ly6 family proteins in neutrophil biology. J Leukoc Biol. 2013;94(4):585–594. doi:10.1189/jlb.0113014.
  • Upadhyay G. Emerging role of lymphocyte antigen-6 family of genes in cancer and immune cells. Front Immunol. 2019;10:819. doi:10.3389/fimmu.2019.00819.
  • Spence JS, He R, Hoffmann H-H, et al. IFITM3 directly engages and shuttles incoming virus particles to lysosomes. Nat Chem Biol. 2019;15(3):259–268. doi:10.1038/s41589-018-0213-2.
  • Feeley EM, Sims JS, John SP, et al. IFITM3 inhibits influenza A virus infection by preventing cytosolic entry. PLoS Pathog. 2011;7(10):e1002337doi:10.1371/journal.ppat.1002337.
  • Wee YS, Roundy KM, Weis JJ, et al. Interferon-inducible transmembrane proteins of the innate immune response act as membrane organizers by influencing clathrin and v-ATPase localization and function. Innate Immun. 2012;18(6):834–845. doi:10.1177/1753425912443392.
  • Huang IC, Bailey CC, Weyer JL, et al. Distinct patterns of IFITM-mediated restriction of filoviruses, SARS coronavirus, and influenza A virus. PLoS Pathog. 2011;7(1):e1001258. doi:10.1371/journal.ppat.1001258.
  • Mar KB, Rinkenberger NR, Boys IN, et al. LY6E mediates an evolutionarily conserved enhancement of virus infection by targeting a late entry step. Nat Commun. 2018;9(1):3603. doi:10.1038/s41467-018-06000-y.
  • Wang K, Chen W, Zhou Y-S, et al. SARS-CoV-2 invades host cells via a novel route: CD147-spike protein. bioRxiv.2020.03.14.988345.
  • Bost P, Giladi A, Liu Y, et al. Amit, I. (2020) Host-Viral Infection Maps Reveal Signatures of Severe COVID-19 Patients. Cell. 2020;181(7):1475–1488.e12., doi:10.1016/j.cell.2020.05.006.
  • Bian H, Zheng Z-H, Wei D, et al. Meplazumab treats COVID-19 pneumonia: an open-labelled, concurrent controlled add-on clinical trial. medRxiv.2020.03.21.20040691.
  • Ohnuma K, Haagmans BL, Hatano R, et al. Inhibition of Middle East respiratory syndrome coronavirus infection by anti-CD26 monoclonal antibody. J Virol. 2013;87(24):13892–13899. doi:10.1128/JVI.02448-13.
  • Raj VS, Mou H, Smits SL, et al. Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC. Nature. 2013;495(7440):251–254. doi:10.1038/nature12005.
  • Morimoto C, Schlossman SF. The structure and function of CD26 in the T-cell immune response. Immunol Rev. 1998;161:55–70. doi:10.1111/j.1600-065x.1998.tb01571.x.
  • Matteucci E, Giampietro O. Dipeptidyl peptidase-4 (CD26): knowing the function before inhibiting the enzyme. Curr Med Chem. 2009;16(23):2943–2951. doi:10.2174/092986709788803114.
  • Earnest JT, Hantak MP, Li K, et al. The tetraspanin CD9 facilitates MERS-coronavirus entry by scaffolding host cell receptors and proteases. PLoS Pathog. 2017;13(7):e1006546. doi:10.1371/journal.ppat.1006546.
  • Millet JK, Whittaker GR. Host cell entry of Middle East respiratory syndrome coronavirus after two-step, furin-mediated activation of the spike protein. Proc Natl Acad Sci USA. 2014;111(42):15214–15219. doi:10.1073/pnas.1407087111.
  • Scobey T, Yount BL, Sims AC, et al. Reverse genetics with a full-length infectious cDNA of the Middle East respiratory syndrome coronavirus. Proc Natl Acad Sci USA. 2013;110(40):16157–16162. doi:10.1073/pnas.1311542110.
  • Raj VS, Smits SL, Provacia LB, et al. Adenosine deaminase acts as a natural antagonist for dipeptidyl peptidase 4-mediated entry of the Middle East respiratory syndrome coronavirus. J Virol. 2014;88(3):1834–1838. doi:10.1128/JVI.02935-13.
  • Kameoka J, Tanaka T, Nojima Y, et al. Direct association of adenosine deaminase with a T cell activation antigen, CD26. Science. 1993;261(5120):466–469. doi:10.1126/science.8101391.
  • van Doremalen N, Miazgowicz KL, Milne-Price S, et al. Host species restriction of Middle East respiratory syndrome coronavirus through its receptor, dipeptidyl peptidase 4. J Virol. 2014;88(16):9220–9232. doi:10.1128/JVI.00676-14.
  • van Doremalen N, Miazgowicz KL, Munster VJ. Mapping the specific amino acid residues that make hamster DPP4 functional as a receptor for Middle East respiratory syndrome coronavirus. J Virol. 2016;90(11):5499–5502. doi:10.1128/JVI.03267-15.
  • Cockrell AS, Peck KM, Yount BL, et al. Mouse dipeptidyl peptidase 4 is not a functional receptor for Middle East respiratory syndrome coronavirus infection. J Virol. 2014;88(9):5195–5199. doi:10.1128/JVI.03764-13.
  • Peck KM, Cockrell AS, Yount BL, et al. Glycosylation of mouse DPP4 plays a role in inhibiting Middle East respiratory syndrome coronavirus infection. J Virol. 2015;89(8):4696–4699. doi:10.1128/JVI.03445-14.
  • Letko M, Miazgowicz K, McMinn R, et al. Adaptive evolution of MERS-CoV to species variation in DPP4. Cell Rep. 2018;24(7):1730–1737. doi:10.1016/j.celrep.2018.07.045.
  • Chen Z, Bao L, Chen C, et al. Human neutralizing monoclonal antibody inhibition of Middle East respiratory syndrome coronavirus replication in the common marmoset. J Infect Dis. 2017;215(12):1807–1815. doi:10.1093/infdis/jix209.
  • Zhang S, Zhou P, Wang P, et al. Structural definition of a unique neutralization epitope on the receptor-binding domain of MERS-CoV spike glycoprotein. Cell Rep. 2018;24(2):441–452. doi:10.1016/j.celrep.2018.06.041.
  • Widagdo W, Okba NMA, Li W, et al. Species-specific colocalization of Middle East respiratory syndrome coronavirus attachment and entry receptors. J Virol. 2019;93(16) doi:10.1128/JVI.00107-19.
  • Widagdo W, Raj VS, Schipper D, et al. Differential expression of the Middle East respiratory syndrome coronavirus receptor in the upper respiratory tracts of humans and dromedary camels. J Virol. 2016;90(9):4838–4842. doi:10.1128/JVI.02994-15.
  • Xiao X, Chakraborti S, Dimitrov AS, et al. The SARS-CoV S glycoprotein: expression and functional characterization. Biochem Biophys Res Commun. 2003;312(4):1159–1164. doi:10.1016/j.bbrc.2003.11.054.
  • Babcock GJ, Esshaki DJ, Thomas WD Jr, et al. Amino acids 270 to 510 of the severe acute respiratory syndrome coronavirus spike protein are required for interaction with receptor. J Virol. 2004;78(9):4552–4560. doi:10.1128/jvi.78.9.4552-4560.2004.
  • Wong SK, Li W, Moore MJ, et al. A 193-amino acid fragment of the SARS coronavirus S protein efficiently binds angiotensin-converting enzyme 2. J Biol Chem. 2004;279(5):3197–3201. doi:10.1074/jbc.C300520200.
  • Walls AC, Tortorici M, Frenz B, et al. Glycan shield and epitope masking of a coronavirus spike protein observed by cryo-electron microscopy. Nat Struct Mol Biol. 2016;23(10):899–905. doi:10.1038/nsmb.3293.
  • Xiong X, Tortorici MA, Snijder J, et al. Glycan shield and fusion activation of a deltacoronavirus spike glycoprotein fine-tuned for enteric infections. J Virol. 2018;92:e01628-17.
  • Rossen JWA, de Beer R, Godeke G-J, et al. The viral spike protein is not involved in the polarized sorting of coronaviruses in epithelial cells. J Virol. 1998;72(1):497–503. doi:10.1128/JVI.72.1.497-503.1998.
  • Du L, Tai W, Yang Y, et al. Introduction of neutralizing immunogenicity index to the rational design of MERS coronavirus subunit vaccines. Nat Commun. 2016;7:13473. doi:10.1038/ncomms13473.
  • Gu H, Xie Z, Li T, et al. Angiotensin-converting enzyme 2 inhibits lung injury induced by respiratory syncytial virus. Sci Rep. 2016;6:19840. doi:10.1038/srep19840.
  • Loo Y-M, Fornek J, Crochet N, et al. Distinct RIG-I and MDA5 signaling by RNA viruses in innate immunity. J Virol. 2008;82(1):335–345. doi:10.1128/JVI.01080-07.
  • Dias Junior AG, Sampaio NG, Rehwinkel J. A balancing act: MDA5 in antiviral immunity and autoinflammation. Trends Microbiol. 2019;27(1):75–85. doi:10.1016/j.tim.2018.08.007.
  • Gralinski LE, Sheahan TP, Morrison TE, et al. Complement activation contributes to severe acute respiratory syndrome coronavirus pathogenesis. mBio. 2018;9(5):e01753-18. doi:10.1128/mBio.01753-18.
  • Perlman S, Dandekar AA. Immunopathogenesis of coronavirus infections: implications for SARS. Nat Rev Immunol. 2005;5(12):917–927. doi:10.1038/nri1732.
  • Cheung CY, Poon LL, Ng IH, et al. Cytokine responses in severe acute respiratory syndrome coronavirus-infected macrophages in vitro: possible relevance to pathogenesis. J Virol. 2005;79(12):7819–7826. doi:10.1128/JVI.79.12.7819-7826.2005.
  • Yilla M, Harcourt BH, Hickman CJ, et al. SARS-coronavirus replication in human peripheral monocytes/macrophages. Virus Res. 2005;107(1):93–101. doi:10.1016/j.virusres.2004.09.004.
  • Tseng CT, Perrone LA, Zhu H, et al. Severe acute respiratory syndrome and the innate immune responses: modulation of effector cell function without productive infection. J Immunol. 2005;174(12):7977–7985. doi:10.4049/jimmunol.174.12.7977.
  • Law HK, Cheung CY, Ng HY, et al. Chemokine up-regulation in SARS-coronavirus-infected, monocyte-derived human dendritic cells. Blood. 2005;106(7):2366–2374. doi:10.1182/blood-2004-10-4166.
  • Hartwig SM, Holman KM, Varga SM. Depletion of alveolar macrophages ameliorates virus-induced disease following a pulmonary coronavirus infection. PLoS One. 2014;9(3):e90720. doi:10.1371/journal.pone.0090720.
  • Anghelina D, Zhao J, Trandem K, et al. Role of regulatory T cells in coronavirus-induced acute encephalitis. Virology. 2009;385(2):358–367. doi:10.1016/j.virol.2008.12.014.
  • Anghelina D, Pewe L, Perlman S. Pathogenic role for virus-specific CD4 T cells in mice with coronavirus-induced acute encephalitis. Am J Pathol. 2006;169(1):209–222. doi:10.2353/ajpath.2006.051308.
  • Spiegel M, Pichlmair A, Martínez-Sobrido L, et al. Inhibition of Beta interferon induction by severe acute respiratory syndrome coronavirus suggests a two-step model for activation of interferon regulatory factor 3. J Virol. 2005;79(4):2079–2086. doi:10.1128/JVI.79.4.2079-2086.2005.
  • Li SW, Yang TC, Wan L, et al. Correlation between TGF-β1 expression and proteomic profiling induced by severe acute respiratory syndrome coronavirus papain-like protease. Proteomics. 2012;12(21):3193–3205. doi:10.1002/pmic.201200225.
  • Lui PY, Wong LY, Fung CL, et al. Middle East respiratory syndrome coronavirus M protein suppresses type I interferon expression through the inhibition of TBK1-dependent phosphorylation of IRF3. Emerg Microbes Infect. 2016;5:e39. doi:10.1038/emi.2016.33.
  • Bouvet M, Debarnot C, Imbert I, et al. In vitro reconstitution of SARS-coronavirus mRNA cap methylation. PLoS Pathog. 2010;6(4):e1000863. doi:10.1371/journal.ppat.1000863.
  • Pichlmair A, Lassnig C, Eberle C-A, et al. IFIT1 is an antiviral protein that recognizes 5'-triphosphate RNA. Nat Immunol. 2011;12(7):624–630. doi:10.1038/ni.2048.
  • Menachery VD, Debbink K, Baric RS. Coronavirus non-structural protein 16: evasion, attenuation, and possible treatments. Virus Res. 2014;194:191–199. doi:10.1016/j.virusres.2014.09.009.
  • Li SW, Wang CY, Jou YJ, et al. SARS coronavirus papain-like protease induces Egr-1-dependent up-regulation of TGF-β1 via ROS/p38 MAPK/STAT3 pathway. Sci Rep. 2016;6:25754. doi:10.1038/srep25754.
  • Wang CY, Lu CY, Li SW, et al. SARS coronavirus papain-like protease up-regulates the collagen expression through non-Samd TGF-β1 signaling. Virus Res. 2017;235:58–66. doi:10.1016/j.virusres.2017.04.008.
  • Chen X, Yang X, Zheng Y, et al. SARS coronavirus papain-like protease inhibits the type I interferon signaling pathway through interaction with the STING-TRAF3-TBK1 complex. Protein Cell. 2014;5(5):369–381. doi:10.1007/s13238-014-0026-3.
  • Sun L, Xing Y, Chen X, et al. Coronavirus papain-like proteases negatively regulate antiviral innate immune response through disruption of STING-mediated signaling. PLoS One. 2012;7(2):e30802. doi:10.1371/journal.pone.0030802.
  • Devaraj SG, Wang N, Chen Z, et al. Regulation of IRF-3-dependent Innate Immunity by the Papain-like Protease Domain of the Severe Acute Respiratory Syndrome Coronavirus. J Biol Chem. 2007;282(44):32208–32221. doi:10.1074/jbc.M704870200.
  • Frieman M, Ratia K, Johnston RE, et al. Severe acute respiratory syndrome coronavirus papain-like protease ubiquitin-like domain and catalytic domain regulate antagonism of IRF3 and NF-kappaB signaling. J Virol. 2009;83(13):6689–6705. doi:10.1128/JVI.02220-08.
  • Li SW, Wang CY, Jou YJ, et al. SARS coronavirus papain-like protease inhibits the TLR7 signaling pathway through removing Lys63-linked polyubiquitination of TRAF3 and TRAF6. Int J Mol Sci. 2016;17.
  • Békés M, van der Heden van Noort GJ, Ekkebus R, et al. Recognition of Lys48-linked di-ubiquitin and deubiquitinating activities of the SARS coronavirus papain-like protease. Mol Cell. 2016;62(4):572–585. doi:10.1016/j.molcel.2016.04.016.
  • Shi H-X, Yang K, Liu X, et al. Positive regulation of interferon regulatory factor 3 activation by Herc5 via ISG15 modification. Mol Cell Biol. 2010;30(10):2424–2436. doi:10.1128/MCB.01466-09.
  • Spiegel M, Schneider K, Weber F, et al. Interaction of severe acute respiratory syndrome-associated coronavirus with dendritic cells. J Gen Virol. 2006;87(Pt 7):1953–1960. doi:10.1099/vir.0.81624-0.
  • Lei Y, Moore CB, Liesman RM, et al. MAVS-mediated apoptosis and its inhibition by viral proteins. PloS One. 2009;4(5):e5466. doi:10.1371/journal.pone.0005466.
  • Yoshikawa T, Hill T, Li K, et al. Severe acute respiratory syndrome (SARS) coronavirus-induced lung epithelial cytokines exacerbate SARS pathogenesis by modulating intrinsic functions of monocyte-derived macrophages and dendritic cells. J Virol. 2009;83(7):3039–3048. doi:10.1128/JVI.01792-08.
  • Qian Z, Travanty EA, Oko L, et al. Innate immune response of human alveolar type II cells infected with severe acute respiratory syndrome-coronavirus. Am J Respir Cell Mol Biol. 2013;48(6):742–748. doi:10.1165/rcmb.2012-0339OC.
  • Wong CK, Lam CW, Wu AK, et al. Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome. Clin Exp Immunol. 2004;136(1):95–103. doi:10.1111/j.1365-2249.2004.02415.x.
  • Wang WK, Chen SY, Liu IJ, et al. Temporal relationship of viral load, ribavirin, interleukin (IL)-6, IL-8, and clinical progression in patients with severe acute respiratory syndrome. Clin Infect Dis. 2004;39(7):1071–1075. doi:10.1086/423808.
  • Zhang Y, Li J, Zhan Y, et al. Analysis of serum cytokines in patients with severe acute respiratory syndrome. Infect Immun. 2004;72(8):4410–4415. doi:10.1128/IAI.72.8.4410-4415.2004.
  • Lee CH, Chen RF, Liu JW, et al. Altered p38 mitogen-activated protein kinase expression in different leukocytes with increment of immunosuppressive mediators in patients with severe acute respiratory syndrome. J Immunol. 2004;172(12):7841–7847. doi:10.4049/jimmunol.172.12.7841.]
  • Chien JY, Hsueh PR, Cheng WC, et al. Temporal changes in cytokine/chemokine profiles and pulmonary involvement in severe acute respiratory syndrome. Respirology. 2006;11(6):715–722. doi:10.1111/j.1440-1843.2006.00942.x.
  • Yen YT, Liao F, Hsiao CH, et al. Modeling the early events of severe acute respiratory syndrome coronavirus infection in vitro. J Virol. 2006;80(6):2684–2693. doi:10.1128/JVI.80.6.2684-2693.2006.
  • Garcia-Vallejo JJ, van Kooyk Y. The physiological role of DC-SIGN: A tale of mice and men. Trends Immunol. 2013;34(10):482–486. doi:10.1016/j.it.2013.03.001.
  • Soilleux EJ. DC-SIGN (dendritic cell-specific ICAM-grabbing non-integrin) and DC-SIGN-related (DC-SIGNR): friend or foe? Clin Sci. 2003;104(4):437–446.
  • Regan AD, Whittaker GR. Utilization of DC-SIGN for Entry of Feline Coronaviruses into Host Cells. J Virol. 2008;82(23):11992–11996. doi:10.1128/JVI.01094-08.
  • Gu J, Gong E, Zhang B, et al. Multiple organ infection and the pathogenesis of SARS. J Exp Med. 2005;202(3):415–424. doi:10.1084/jem.20050828.
  • Channappanavar R, Zhao J, Perlman S. T cell-mediated immune response to respiratory coronaviruses. Immunol Res. 2014;59(1-3):118–128. doi:10.1007/s12026-014-8534-z.
  • Channappanavar R, Fehr AR, Vijay R, et al. Dysregulated type i interferon and inflammatory monocyte-macrophage responses cause lethal pneumonia in SARS-CoV-infected mice. Cell Host Microbe. 2016;19(2):181–193. doi:10.1016/j.chom.2016.01.007.
  • Channappanavar R, Fett C, Zhao J, et al. Virus-specific memory CD8 T cells provide substantial protection from lethal severe acute respiratory syndrome coronavirus infection. J Virol. 2014;88(19):11034–11044. doi:10.1128/JVI.01505-14.
  • Sheahan T, Morrison TE, Funkhouser W, et al. MyD88 is required for protection from lethal infection with a mouse-adapted SARS-CoV. PLoS Pathog. 2008;4(12):e1000240. doi:10.1371/journal.ppat.1000240.
  • Deguine J, Barton GM. MyD88: a central player in innate immune signaling. F1000Prime Rep. 2014;6:97–97. doi:10.12703/P6-97.
  • Butchi N, Kapil P, Puntambekar S, et al. Myd88 initiates early innate immune responses and promotes CD4 T cells during coronavirus encephalomyelitis. J Virol. 2015;89(18):9299–9312. doi:10.1128/JVI.01199-15.
  • Loures FV, Pina A, Felonato M, et al. MyD88 signaling is required for efficient innate and adaptive immune responses to Paracoccidioides brasiliensis infection. Infect Immun. 2011;79:2470–2480.
  • Frieman MB, Chen J, Morrison TE, et al. SARS-CoV pathogenesis is regulated by a STAT1 dependent but a type I, II and III interferon receptor independent mechanism. PLoS Pathog. 2010;6(4):e1000849. doi:10.1371/journal.ppat.1000849.
  • Freundt EC, Yu L, Goldsmith CS, et al. The open reading frame 3a protein of severe acute respiratory syndrome-associated coronavirus promotes membrane rearrangement and cell death. J Virol. 2010;84(2):1097–1109. doi:10.1128/JVI.01662-09.
  • Freundt EC, Yu L, Park E, et al. Molecular determinants for subcellular localization of the severe acute respiratory syndrome coronavirus open reading frame 3b protein. J Virol. 2009;83(13):6631–6640. doi:10.1128/JVI.00367-09.
  • Kopecky-Bromberg SA, Martínez-Sobrido L, Frieman M, Baric RA, Palese P. Severe acute respiratory syndrome coronavirus open reading frame (ORF) 3b, ORF 6, and nucleocapsid proteins function as interferon antagonists. J Virol. 2007;81(2):548–557. doi:10.1128/JVI.01782-06.
  • Yue Y, Nabar NR, Shi CS, et al. SARS-coronavirus open reading frame-3a drives multimodal necrotic cell death. Cell Death Dis. 2018;9(9):904. doi:10.1038/s41419-018-0917-y.
  • Shi CS, Nabar NR, Huang NN, et al. SARS-coronavirus open reading frame-8b triggers intracellular stress pathways and activates NLRP3 inflammasomes. Cell Death Discov. 2019;5:101. doi:10.1038/s41420-019-0181-7.
  • Morales L, Oliveros JC, Fernandez-Delgado R, et al. SARS-CoV-encoded small RNAs contribute to infection-associated lung pathology. Cell Host Microbe. 2017;21(3):344–355. doi:10.1016/j.chom.2017.01.015.
  • Haller O, Staeheli P, Schwemmle M, Kochs G. Mx GTPases: dynamin-like antiviral machines of innate immunity. Trends Microbiol. 2015;23(3):154–163. doi:10.1016/j.tim.2014.12.003.
  • Perng Y-C, Lenschow DJ. ISG15 in antiviral immunity and beyond. Nat Rev Microbiol. 2018;16(7):423–439. doi:10.1038/s41579-018-0020-5.
  • Daczkowski CM, Dzimianski JV, Clasman JR, et al. Structural insights into the interaction of coronavirus papain-like proteases and interferon-stimulated gene product 15 from different species. J Mol Biol. 2017;429(11):1661–1683. doi:10.1016/j.jmb.2017.04.011.
  • Lindner HA, Lytvyn V, Qi H, et al. Selectivity in ISG15 and ubiquitin recognition by the SARS coronavirus papain-like protease. Arch Biochem Biophys. 2007;466(1):8–14. doi:10.1016/j.abb.2007.07.006.
  • Memish ZA, Perlman S, Van Kerkhove MD, et al. Middle East respiratory syndrome. Lancet. 2020;395(10229):1063–1077. doi:10.1016/S0140-6736(19)33221-0.
  • Ng DL, Al Hosani F, Keating MK, et al. Clinicopathologic, immunohistochemical, and ultrastructural findings of a fatal case of Middle East Respiratory syndrome coronavirus infection in the United Arab Emirates, April 2014. Am J Pathol. 2016;186(3):652–658. doi:10.1016/j.ajpath.2015.10.024.
  • Kim ES, Choe PG, Park WB, et al. Clinical progression and cytokine profiles of Middle East respiratory syndrome coronavirus infection. J Korean Med Sci. 2016;31(11):1717–1725. doi:10.3346/jkms.2016.31.11.1717.
  • Min C-K, Cheon S, Ha N-Y, et al. Comparative and kinetic analysis of viral shedding and immunological responses in MERS patients representing a broad spectrum of disease severity. Sci Rep. 2016;6:25359. doi:10.1038/srep25359.
  • Siu KL, Yeung ML, Kok KH, et al. Middle east respiratory syndrome coronavirus 4a protein is a double-stranded RNA-binding protein that suppresses PACT-induced activation of RIG-I and MDA5 in the innate antiviral response. J Virol. 2014;88(9):4866–4876. doi:10.1128/JVI.03649-13.
  • Kok K-H, Lui P-Y, Ng M, Him J, et al. The double-stranded RNA-binding protein PACT functions as a cellular activator of RIG-I to facilitate innate antiviral response. Cell Host Microbe. 2011;9(4):299–309. doi:10.1016/j.chom.2011.03.007.
  • Mielech AM, Kilianski A, Baez-Santos YM, et al. MERS-CoV papain-like protease has deISGylating and deubiquitinating activities. Virology. 2014;450-451:64–70. doi:10.1016/j.virol.2013.11.040.
  • Fitzgerald KA, McWhirter SM, Faia KL, et al. IKKepsilon and TBK1 are essential components of the IRF3 signaling pathway. Nat Immunol. 2003;4(5):491–496. doi:10.1038/ni921.
  • Banerjee A, Baid K, Mossman K. Molecular pathogenesis of Middle East respiratory syndrome (MERS) coronavirus. Curr Clin Microbiol Rep. 2019;6(3):139–147. doi:10.1007/s40588-019-00122-7.
  • Niemeyer D, Zillinger T, Muth D, et al. Middle East respiratory syndrome coronavirus accessory protein 4a is a type I interferon antagonist. J Virol. 2013;87(22):12489–12495. doi:10.1128/JVI.01845-13.
  • Yang Y, Zhang L, Geng H, et al. The structural and accessory proteins M, ORF 4a, ORF 4b, and ORF 5 of Middle East respiratory syndrome coronavirus (MERS-CoV) are potent interferon antagonists. Protein Cell. 2013;4(12):951–961. doi:10.1007/s13238-013-3096-8.
  • Canton J, Fehr AR, Fernandez-Delgado R, et al. MERS-CoV 4b protein interferes with the NF-κB-dependent innate immune response during infection. PLoS Pathog. 2018;14(1):e1006838. doi:10.1371/journal.ppat.1006838.
  • Shokri S, Mahmoudvand S, Taherkhani R, et al. Modulation of the immune response by Middle East respiratory syndrome coronavirus. J Cell Physiol. 2019;234(3):2143–2151. doi:10.1002/jcp.27155.
  • Deng X, Hackbart M, Mettelman RC, et al. Coronavirus nonstructural protein 15 mediates evasion of dsRNA sensors and limits apoptosis in macrophages. Proc Natl Acad Sci USA. 2017;114(21):E4251–e4260. doi:10.1073/pnas.1618310114.
  • Thornbrough JM, Jha BK, Yount B, et al. Middle East Respiratory syndrome coronavirus NS4b protein inhibits host RNase L activation. mBio. 2016;7(2):e00258. doi:10.1128/mBio.00258-16.
  • Zhao J, Li K, Wohlford-Lenane C, et al. Rapid generation of a mouse model for Middle East respiratory syndrome. Proc Natl Acad Sci USA. 2014;111(13):4970–4975. doi:10.1073/pnas.1323279111.
  • Falzarano D, de Wit E, Rasmussen AL, et al. Treatment with interferon-α2b and ribavirin improves outcome in MERS-CoV-infected rhesus macaques. Nat Med. 2013;19(10):1313–1317. doi:10.1038/nm.3362.
  • Lau SKP, Lau CCY, Chan KH, et al. Delayed induction of proinflammatory cytokines and suppression of innate antiviral response by the novel Middle East respiratory syndrome coronavirus: implications for pathogenesis and treatment. J Gen Virol. 2013;94(Pt 12):2679–2690. doi:10.1099/vir.0.055533-0.
  • Zhou J, Chu H, Li C, et al. Active replication of Middle East respiratory syndrome coronavirus and aberrant induction of inflammatory cytokines and chemokines in human macrophages: implications for pathogenesis. J Infect Dis. 2014;209(9):1331–1342. doi:10.1093/infdis/jit504.
  • Tynell J, Westenius V, Rönkkö E, et al. Middle East respiratory syndrome coronavirus shows poor replication but significant induction of antiviral responses in human monocyte-derived macrophages and dendritic cells. J Gen Virol. 2016;97(2):344–355. doi:10.1099/jgv.0.000351.
  • Chu H, Zhou J, Wong BH, et al. Middle East respiratory syndrome coronavirus efficiently infects human primary T lymphocytes and activates the extrinsic and intrinsic apoptosis pathways. J Infect Dis. 2016;213(6):904–914. doi:10.1093/infdis/jiv380.
  • Chu H, Zhou J, Wong BH, et al. Productive replication of Middle East respiratory syndrome coronavirus in monocyte-derived dendritic cells modulates innate immune response. Virology. 2014;454-455:197–205. doi:10.1016/j.virol.2014.02.018.
  • Scheuplein VA, Seifried J, Malczyk AH, et al. High secretion of interferons by human plasmacytoid dendritic cells upon recognition of Middle East respiratory syndrome coronavirus. J Virol. 2015;89(7):3859–3869. doi:10.1128/JVI.03607-14.
  • Prescott J, Falzarano D, de Wit E, et al. Pathogenicity and viral shedding of MERS-CoV in immunocompromised rhesus macaques. Front Immunol. 2018;9:205–205. doi:10.3389/fimmu.2018.00205.
  • Coleman CM, Sisk JM, Halasz G, et al. CD8+ T cells and macrophages regulate pathogenesis in a mouse model of Middle East respiratory syndrome. J Virol. 2017;91(1) doi:10.1128/JVI.01825-16.
  • Baseler LJ, Falzarano D, Scott DP, et al. An acute immune response to Middle East respiratory syndrome coronavirus replication contributes to viral pathogenicity. Am J Pathol. 2016;186(3):630–638. doi:10.1016/j.ajpath.2015.10.025.
  • Yu P, Xu Y, Deng W, et al. Comparative pathology of rhesus macaque and common marmoset animal models with Middle East respiratory syndrome coronavirus. PLoS One. 2017;12(2):e0172093. doi:10.1371/journal.pone.0172093.
  • Li K, Wohlford-Lenane CL, Channappanavar R, et al. Mouse-adapted MERS coronavirus causes lethal lung disease in human DPP4 knockin mice. Proc Natl Acad Sci USA. 2017;114(15):E3119–e3128. doi:10.1073/pnas.1619109114.
  • Channappanavar R, Fehr AR, Zheng J, et al. IFN-I response timing relative to virus replication determines MERS coronavirus infection outcomes. J Clin Invest. 2019;129(9):3625–3639. doi:10.1172/JCI126363.
  • Zhao J, Yuan Q, Wang H, et al. Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease. Clin Infect Dis. 2020;2020:ciaa344.
  • Long Q-X, Tang X-J, Shi Q-L, et al. Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections. Nat Med. 2020.
  • Chen G, Wu D, Guo W, et al. Clinical and immunological features of severe and moderate coronavirus disease 2019. J Clin Invest. 2020;130(5):2620–2629. doi:10.1172/JCI137244.
  • Thevarajan I, Nguyen THO, Koutsakos M, et al. Breadth of concomitant immune responses prior to patient recovery: a case report of non-severe COVID-19. Nat Med. 2020;26(4):453–455. doi:10.1038/s41591-020-0819-2.
  • Seydoux E, Homad LJ, MacCamy AJ, et al. Analysis of a SARS-CoV-2-infected individual reveals development of potent neutralizing antibodies with limited somatic mutation. Immunity. 2020;53(1):98–105.e5. doi:10.1016/j.immuni.2020.06.001.
  • Vieira Braga FA, Hertoghs KM, Kragten NA, et al. Blimp-1 homolog Hobit identifies effector-type lymphocytes in humans. Eur J Immunol. 2015;45(10):2945–2958. doi:10.1002/eji.201545650.
  • Kragten NAM, Behr FM, Vieira Braga FA, et al. Blimp-1 induces and Hobit maintains the cytotoxic mediator granzyme B in CD8 T cells. Eur J Immunol. 2018;48(10):1644–1662. doi:10.1002/eji.201847771.
  • Behr FM, Kragten NAM, Wesselink TH, et al. Blimp-1 rather than hobit drives the formation of tissue-resident memory CD8+ T cells in the lungs. Front Immunol. 2019;10:400. doi:10.3389/fimmu.2019.00400.
  • Post M, Cuapio A, Osl M, et al. The transcription factor ZNF683/HOBIT regulates human NK-cell development. Front Immunol. 2017;8:535. doi:10.3389/fimmu.2017.00535.
  • Pedersen SF, Ho YC. SARS-CoV-2: A storm is raging. J Clin Invest. 2020.
  • Meckiff BJ, Ramírez-Suástegui C, Fajardo V, et al. Single-cell transcriptomic analysis of SARS-CoV-2 reactive CD4+ T cells. bioRxiv.2020.06.12.148916.
  • Weiskopf D, Schmitz KS, Raadsen MP, et al. Phenotype of SARS-CoV-2-specific T-cells in COVID-19 patients with acute respiratory distress syndrome. medRxiv.2020.04.11.20062349.
  • Grifoni A, Weiskopf D, Ramirez SI, et al. Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals. Cell. 2020;181(7):1489–1501.e15. doi:10.1016/j.cell.2020.05.015.
  • Ni L, Ye F, Cheng M-L, et al. Detection of SARS-CoV-2-specific humoral and cellular immunity in COVID-19 convalescent individuals. Immunity. 2020;52(6):971–977.e3. doi:10.1016/j.immuni.2020.04.023.
  • Giamarellos-Bourboulis EJ, Netea MG, Rovina N, et al. Complex immune dysregulation in COVID-19 patients with severe respiratory failure. Cell Host Microbe. 2020;27(6):992–1000.e3. doi:10.1016/j.chom.2020.04.009.
  • Wilk AJ, Rustagi A, Zhao NQ, et al. A single-cell atlas of the peripheral immune response in patients with severe COVID-19. Nat Med. 2020;26(7):1070–1076. ) doi:10.1038/s41591-020-0944-y.
  • Dimopoulos G, de Mast Q, Markou N, et al. Favorable anakinra responses in severe Covid-19 patients with secondary hemophagocytic lymphohistiocytosis. Cell Host Microbe. 2020;28(1):117–123.e1. doi:10.1016/j.chom.2020.05.007.
  • Franzetti M, Pozzetti U, Carugati M, et al. Interleukin-1 receptor antagonist anakinra in association with remdesivir in severe Coronavirus disease 2019: a case report. Int J Infect Dis. 2020;97:215–218. ) doi:10.1016/j.ijid.2020.05.050.
  • Wang Y, Zhang D, Du G, et al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet. 2020;395(10236):1569–1578. doi:10.1016/S0140-6736(20)31022-9.
  • Grein J, Ohmagari N, Shin D, et al. Compassionate use of remdesivir for patients with severe Covid-19. N Engl J Med. 2020;382(24):2327–2336. doi:10.1056/NEJMoa2007016.
  • Zhao C, Zhao W. NLRP3 inflammasome: a key player in antiviral responses. Front Immunol. 2020;11:211. doi:10.3389/fimmu.2020.00211.
  • Chen IY, Ichinohe T. Response of host inflammasomes to viral infection. Trends Microbiol. 2015;23(1):55–63. doi:10.1016/j.tim.2014.09.007.
  • Martín-Sánchez F, Diamond C, Zeitler M, et al. Inflammasome-dependent IL-1β release depends upon membrane permeabilisation. Cell Death Differ. 2016;23(7):1219–1231. doi:10.1038/cdd.2015.176.
  • Ghiringhelli F, Apetoh L, Tesniere A, et al. Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors. Nat Med. 2009;15(10):1170–1178. doi:10.1038/nm.2028.
  • Johnson JL, Ramadass M, Haimovich A, et al. Increased neutrophil secretion induced by NLRP3 mutation links the inflammasome to azurophilic granule exocytosis. Front Cell Infect Microbiol. 2017;7:507. doi:10.3389/fcimb.2017.00507.
  • Ong EZ, Chan YFZ, Leong WY, et al. A dynamic immune response shapes COVID-19 progression. Cell Host Microbe. 2020;27(6):879–882.e2. doi:10.1016/j.chom.2020.03.021.
  • Cugno M, Meroni PL, Gualtierotti R, et al. Complement activation in patients with COVID-19: A novel therapeutic target. J Allergy Clin Immunol. 2020;146(1):215–217. doi:10.1016/j.jaci.2020.05.006.
  • Gao T, Hu M, Zhang X, et al. Highly pathogenic coronavirus N protein aggravates lung injury by MASP-2-mediated complement over-activation. medRxiv.2020.03.29.20041962.
  • Zheng M, Gao Y, Wang G, et al. Functional exhaustion of antiviral lymphocytes in COVID-19 patients. Cell Mol Immunol. 2020;17(5):533–535. doi:10.1038/s41423-020-0402-2.
  • Hadjadj J, Yatim N, Barnabei L, et al. Impaired type I interferon activity and exacerbated inflammatory responses in severe Covid-19 patients. medRxiv.2020.04.19.20068015.
  • Gruber C. Impaired interferon signature in severe COVID-19. Nat Rev Immunol. 2020;20(6):353–353. doi:10.1038/s41577-020-0335-0.
  • Zhang B, Zhou X, Zhu C, et al. Immune phenotyping based on neutrophil-to-lymphocyte ratio and IgG predicts disease severity and outcome for patients with COVID-19. medRxiv.2020.03.12.20035048.
  • Liu J, Liu Y, Xiang P, et al. Neutrophil-to-lymphocyte ratio predicts critical illness patients with 2019 coronavirus disease in the early stage. J Transl Med. 2020;18(1):206. doi:10.1186/s12967-020-02374-0.
  • Zhou Y, Fu B, Zheng X, et al. Aberrant pathogenic GM-CSF+ T cells and inflammatory CD14+CD16+ monocytes in severe pulmonary syndrome patients of a new coronavirus. bioRxiv.2020.02.12.945576.
  • Razvi ES, Welsh RM. Programmed cell death of T lymphocytes during acute viral infection: a mechanism for virus-induced immune deficiency. J Virol. 1993;67(10):5754–5765. doi:10.1128/JVI.67.10.5754-5765.1993.
  • Blanco-Melo D, Nilsson-Payant BE, Liu WC, et al. Imbalanced host response to SARS-CoV-2 drives development of COVID-19. Cell. 2020;181(5):1036–1045.e9. doi:10.1016/j.cell.2020.04.026.
  • Zhou Z, Ren L, Zhang L, et al. Heightened innate immune responses in the respiratory tract of COVID-19 patients. Cell Host Microbe. 2020;27(6):883–890.e2. doi:10.1016/j.chom.2020.04.017.
  • Liao M, Liu Y, Yuan J, et al. Single-cell landscape of bronchoalveolar immune cells in patients with COVID-19. Nat Med. 2020;26(6):842–844. doi:10.1038/s41591-020-0901-9.
  • Zhang D, Guo R, Lei L, et al. COVID-19 infection induces readily detectable morphological and inflammation-related phenotypic changes in peripheral blood monocytes, the severity of which correlate with patient outcome. medRxiv.2020.03.24.20042655.
  • Oksanen A, Aittomäki S, Jankovic D, et al. Proprotein convertase FURIN constrains Th2 differentiation and is critical for host resistance against Toxoplasma gondii. J Immunol. 2014;193(11):5470–5479. doi:10.4049/jimmunol.1401629.
  • Rubtsova K, Rubtsov AV, Halemano K, et al. T cell production of IFNγ in response to TLR7/IL-12 stimulates optimal B cell responses to viruses. PLoS ONE. 2016;11(11):e0166322. doi:10.1371/journal.pone.0166322.
  • Mittal SK, Roche PA. Suppression of antigen presentation by IL-10. Curr Opin Immunol. 2015;34:22–27. doi:10.1016/j.coi.2014.12.009.
  • Rojas JM, Avia M, Martín V, et al. IL-10: a multifunctional cytokine in viral infections. J Immunol Res. 2017;2017:6104054. doi:10.1155/2017/6104054.
  • Moore KW, de Waal Malefyt R, Coffman RL, et al. Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol. 2001;19:683–765. doi:10.1146/annurev.immunol.19.1.683.
  • Itoh K, Hirohata S. The role of IL-10 in human B cell activation, proliferation, and differentiation. J Immunol. 1995;154:4341–4350.
  • Malisan F, Brière F, Bridon JM, et al. Interleukin-10 induces immunoglobulin G isotype switch recombination in human CD40-activated naive B lymphocytes. J Exp Med. 1996;183(3):937–947. doi:10.1084/jem.183.3.937.
  • Gary-Gouy H, Harriague J, Bismuth G, et al. Human CD5 promotes B-cell survival through stimulation of autocrine IL-10 production. Blood. 2002;100(13):4537–4543. doi:10.1182/blood-2002-05-1525.
  • Shparago N, Zelazowski P, Jin L, et al. IL-10 selectively regulates murine Ig isotype switching. Int Immunol. 1996;8(5):781–790. doi:10.1093/intimm/8.5.781.
  • Parker DC. T cell-dependent B cell activation. Annu Rev Immunol. 1993;11:331–360. doi:10.1146/annurev.iy.11.040193.001555.
  • Noelle RJ, Roy M, Shepherd DM, Stamenkovic I, Ledbetter JA, Aruffo A. A 39-kDa protein on activated helper T cells binds CD40 and transduces the signal for cognate activation of B cells. Proc Natl Acad Sci USA. 1992;89(14):6550–6554. doi:10.1073/pnas.89.14.6550.
  • Gordon DE, Jang GM, Bouhaddou M, et al. A SARS-CoV-2-human protein-protein interaction map reveals drug targets and potential drug-repurposing. bioRxiv.2020.03.22.002386.
  • Zhang X, Li X, Ning F, et al. TLE4 acts as a corepressor of Hes1 to inhibit inflammatory responses in macrophages. Protein Cell. 2019;10(4):300–305. doi:10.1007/s13238-018-0554-3.
  • Ramasamy S, Saez B, Mukhopadhyay S, et al. Tle1 tumor suppressor negatively regulates inflammation in vivo and modulates NF-κB inflammatory pathway. Proc Natl Acad Sci USA. 2016;113(7):1871–1876. doi:10.1073/pnas.1511380113.
  • Wang C, Chen T, Zhang J, et al. The E3 ubiquitin ligase Nrdp1 'preferentially' promotes TLR-mediated production of type I interferon. Nat Immunol. 2009;10(7):744–752. doi:10.1038/ni.1742.
  • Kondo T, Watanabe M, Hatakeyama S. TRIM59 interacts with ECSIT and negatively regulates NF-κB and IRF-3/7-mediated signal pathways. Biochem Biophys Res Commun. 2012;422(3):501–507. doi:10.1016/j.bbrc.2012.05.028.
  • Kumagai Y, Akira S. Mind bomb proteins in the antiviral arsenal. Immunity. 2011;35(3):320–322. doi:10.1016/j.immuni.2011.09.003.
  • Li S, Wang L, Berman M, et al. Mapping a dynamic innate immunity protein interaction network regulating type I interferon production. Immunity. 2011;35(3):426–440. doi:10.1016/j.immuni.2011.06.014.
  • Xia X, Cui J, Wang HY, et al. NLRX1 negatively regulates TLR-induced NF-κB signaling by targeting TRAF6 and IKK. Immunity. 2011;34(6):843–853. doi:10.1016/j.immuni.2011.02.022.
  • Allen IC, Moore CB, Schneider M, et al. NLRX1 protein attenuates inflammatory responses to infection by interfering with the RIG-I-MAVS and TRAF6-NF-κB signaling pathways. Immunity. 2011;34(6):854–865. doi:10.1016/j.immuni.2011.03.026.
  • Nagai-Singer MA, Morrison HA, Allen IC. NLRX1 is a multifaceted and enigmatic regulator of immune system function. Front Immunol. 2019;10:2419. doi:10.3389/fimmu.2019.02419.
  • Hung SC, Huang PR, Almeida-da-Silva CLC, et al. NLRX1 modulates differentially NLRP3 inflammasome activation and NF-κB signaling during Fusobacterium nucleatum infection. Microbes Infect. 2018;20(9-10):615–625. doi:10.1016/j.micinf.2017.09.014.
  • Chi H, Zheng X, Wang X, et al. DNA vaccine encoding Middle East respiratory syndrome coronavirus S1 protein induces protective immune responses in mice. Vaccine. 2017;35(16):2069–2075. doi:10.1016/j.vaccine.2017.02.063.
  • Lu G, Hu Y, Wang Q, et al. Molecular basis of binding between novel human coronavirus MERS-CoV and its receptor CD26. Nature. 2013;500(7461):227–231. doi:10.1038/nature12328.
  • Song W, Gui M, Wang X, Xiang Y. Cryo-EM structure of the SARS coronavirus spike glycoprotein in complex with its host cell receptor ACE2. PLoS Pathog. 2018;14(8):e1007236. doi:10.1371/journal.ppat.1007236.
  • Du L, He Y, Zhou Y, et al. The spike protein of SARS-CoV-a target for vaccine and therapeutic development. Nat Rev Microbiol. 2009;7(3):226–236. doi:10.1038/nrmicro2090.
  • Czub M, Weingartl H, Czub S, et al. Evaluation of modified vaccinia virus Ankara based recombinant SARS vaccine in ferrets. Vaccine. 2005;23(17-18):2273–2279. doi:10.1016/j.vaccine.2005.01.033.
  • Weingartl H, Czub M, Czub S, et al. Immunization with modified vaccinia virus Ankara-based recombinant vaccine against severe acute respiratory syndrome is associated with enhanced hepatitis in ferrets. J Virol. 2004;78(22):12672–12676. doi:10.1128/JVI.78.22.12672-12676.2004.
  • Monteil V, Kwon H, Prado P, et al. Inhibition of SARS-CoV-2 infections in engineered human tissues using clinical-grade soluble human ACE2. Cell. 2020;181(4):905–913.e7. doi:10.1016/j.cell.2020.04.004.
  • Khan A, Benthin C, Zeno B, et al. A pilot clinical trial of recombinant human angiotensin-converting enzyme 2 in acute respiratory distress syndrome. Crit Care. 2017;21(1):234. doi:10.1186/s13054-017-1823-x.
  • Iwanaga N, Cooper L, Rong L, et al. Novel ACE2-IgG1 fusions with improved activity against SARS-CoV2. bioRxiv. 2020.
  • Liu J, Cao R, Xu M, et al. Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro. Cell Discov. 2020;6:16. doi:10.1038/s41421-020-0156-0.
  • Keyaerts E, Vijgen L, Maes P, et al. In vitro inhibition of severe acute respiratory syndrome coronavirus by chloroquine. Biochem Biophys Res Commun. 2004;323(1):264–268. doi:10.1016/j.bbrc.2004.08.085.
  • Vincent MJ, Bergeron E, Benjannet S, et al. Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. Virol J. 2005;2:69doi:10.1186/1743-422X-2-69.
  • Inglot AD. Comparison of the antiviral activity in vitro of some non-steroidal anti-inflammatory drugs. J Gen Virol. 1969;4(2):203–214. doi:10.1099/0022-1317-4-2-203.
  • Gao J, Tian Z, Yang X. Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Biosci Trends. 2020;14(1):72–73. doi:10.5582/bst.2020.01047.
  • Yang N, Shen H-M. Targeting the endocytic pathway and autophagy process as a novel therapeutic strategy in COVID-19. Int J Biol Sci. 2020;16(10):1724–1731. doi:10.7150/ijbs.45498.
  • Tang W, Cao Z, Han M, et al. Hydroxychloroquine in patients with COVID-19: an open-label, randomized, controlled trial. medRxiv.2020.04.10.20060558.
  • Chorin E, Dai M, Shulman E, et al. The QT interval in patients with COVID-19 treated with hydroxychloroquine and azithromycin. Nat Med. 2020;26(6):808–809. doi:10.1038/s41591-020-0888-2.
  • Boulware DR, Pullen MF, Bangdiwala AS, et al. A randomized trial of hydroxychloroquine as postexposure prophylaxis for Covid-19. N Engl J Med. 2020.
  • Elfiky AA. Anti-HCV, nucleotide inhibitors, repurposing against COVID-19. Life Sci. 2020;248:117477. doi:10.1016/j.lfs.2020.117477.
  • Cao B, Wang Y, Wen D, et al. A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19. N Engl J Med. 2020;382(19):1787–1799. doi:10.1056/NEJMoa2001282.
  • Hung IF-N, Lung K-C, Tso EY-K, et al. Triple combination of interferon beta-1b, lopinavir–ritonavir. Lancet. 2020;395(10238):1695–1704. doi:10.1016/S0140-6736(20)31042-4.
  • Xia S, Liu M, Wang C, et al. Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion . Cell Res. 2020;30(4):343–355. doi:10.1038/s41422-020-0305-x.
  • Sheahan TP, Sims AC, Graham RL, et al. Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses. Sci Transl Med. 2017;9(396):eaal3653. doi:10.1126/scitranslmed.aal3653.
  • Bouhaddou M, Memon D, Meyer B, et al. The global phosphorylation landscape of SARS-CoV-2 infection. Cell. 2020; doi:10.1016/j.cell.2020.06.034.
  • Huo J, Zhao Y, Ren J, et al. Neutralization of SARS-CoV-2 by destruction of the prefusion spike. Cell Host Microbe. 2020; doi:10.1016/j.chom.2020.06.010.
  • Roschewski M, Lionakis MS, Sharman JP, et al. Inhibition of Bruton tyrosine kinase in patients with severe COVID-19. Sci Immunol. 2020;5(48):eabd0110. doi:10.1126/sciimmunol.abd0110.
  • Campochiaro C, Della-Torre E, Cavalli G, et al. Efficacy and safety of tocilizumab in severe COVID-19 patients: a single-centre retrospective cohort study. Eur J Intern Med. 2020;76:43–49. doi:10.1016/j.ejim.2020.05.021.
  • Toniati P, Piva S, Cattalini M, et al. Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: A single center study of 100 patients in Brescia, Italy. Autoimmun Rev. 2020;19(7):102568doi:10.1016/j.autrev.2020.102568.
  • Vikse J, Henry BM. Tocilizumab in COVID-19: Beware the risk of intestinal perforation. Int J Antimicrob Agents. 2020;56(1):106009. doi:10.1016/j.ijantimicag.2020.106009.
  • Lythgoe MP, Middleton P. Ongoing clinical trials for the management of the COVID-19 pandemic. Trends Pharmacol Sci. 2020;41(6):363–382. doi:10.1016/j.tips.2020.03.006.
  • Shen C, Wang Z, Zhao F, et al. Treatment of 5 critically ill patients with COVID-19 with convalescent plasma. JAMA. 2020;323(16):1582. doi:10.1001/jama.2020.4783.
  • Joyner MJ, Wright RS, Fairweather D, et al. Early safety indicators of COVID-19 convalescent plasma in 5,000 patients. J Clin Invest. 2020.
  • Casadevall A, Pirofski L-A. The convalescent sera option for containing COVID-19. J Clin Invest. 2020;130(4):1545–1548. doi:10.1172/JCI138003.
  • Bloch EM, Shoham S, Casadevall A, et al. Deployment of convalescent plasma for the prevention and treatment of COVID-19. J Clin Invest. 2020;130(6):2757–2765. doi:10.1172/JCI138745.
  • Grifoni A, Sidney J, Zhang Y, Scheuermann RH, Peters B, Sette A. A sequence homology and bioinformatic approach can predict candidate targets for immune responses to SARS-CoV-2. Cell Host Microbe. 2020;27(4):671–680.e2. doi:10.1016/j.chom.2020.03.002.
  • Cao Y, Su B, Guo X, et al. Potent neutralizing antibodies against SARS-CoV-2 identified by high-throughput single-cell sequencing of convalescent patients’ B Cells. Cell. 2020;182(1):73–84.e16. doi:10.1016/j.cell.2020.05.025.
  • Kreer C, Zehner M, Weber T, et al. Longitudinal isolation of potent near-germline SARS-CoV-2-neutralizing antibodies from COVID-19 patients. Cell. In press. doi:10.1016/j.cell.2020.06.044
  • Thomas G. Furin at the cutting edge: from protein traffic to embryogenesis and disease. Nat Rev Mol Cell Biol. 2002;3(10):753–766. doi:10.1038/nrm934.
  • Klimpel KR, Molloy SS, Thomas G, et al. Anthrax toxin protective antigen is activated by a cell surface protease with the sequence specificity and catalytic properties of furin. Proc Natl Acad Sci USA. 1992;89(21):10277–10281. doi:10.1073/pnas.89.21.10277.
  • Xie X, Muruato A, Lokugamage KG, et al. An infectious cDNA clone of SARS-CoV-2. Cell Host Microbe. 2020;27(5):841–848.e3. doi:10.1016/j.chom.2020.04.004.
  • Jiang R-D, Liu M-Q, Chen Y, et al. Pathogenesis of SARS-CoV-2 in transgenic mice expressing human angiotensin-converting enzyme 2. Cell. 2020;182(1):50–P85. P5doi:10.1016/j.cell.2020.05.027.
  • Hassan AO, Case JB, Winkler ES, et al. A SARS-CoV-2 Infection Model in Mice Demonstrates Protection by Neutralizing Antibodies. Cell. In press. doi:10.1016/j.cell.2020.06.011.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.